YEDİTEPE UNIVERSITY
FACULTY of MEDICINE
PHASE III
ACADEMIC PROGRAM BOOK
2014 – 2015
Student’s :
Name:......................................
Number:..................................
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
CONTENTS
Page
AIMS AND OUTCOMES OF MEDICAL EDUCATION PROGRAM....................... 1
PHASE III COORDINATION COMMITTEE........................................................... 5
DESCRIPTION OF THE PHASE .......................................................................... 6
PHASE CONTENT .............…………………………............................................... 6
EXECUTIVES OF ACADEMIC YEAR …………………………………......... ........... 6
AIMS AND OBJECTIVES OF PHASE III................................................................ 7
ACADEMIC CALENDAR 2014 - 2015................................................................... 10
STUDENT COUNSELING..................................................................................... 12
LIST OF STUDENT COUNSELING...................................................................... 13
ASSESSMENTS OF PHASE III............................................................................ 15
SCIENTIFIC PROJECTS...................................................................................... 18
COMMITTEE I INFECTIOUS DISEASES............................................................ 19
COMMITTEE II CARDIOLOGY AND RESPIRATORY SYSTEM.......................... 29
COMMITTEE III HEMATOPOIETIC SYSTEM..................................................... .42
COMMITTEE IV GASTROINTESTINAL SYSTEM.................................................50
COMMITTEE V ENDOCRINE SYSTEM & REPRODUCTIVE SYSTEM................59
COMMITTEE VI URINARY SYSTEM ....................................................................68
COMMITTEE VII NERVOUS SYSTEM & PSYCHIATRY.......................................77
COMMITTEE VIII MUSCULOSKELETAL SYSTEM...............................................88
CONTACT INFORMATION………………………………………………....................97
YEDİTEPE UNIVERSITY FACULTY OF MEDICINE
AIM AND OUTCOMES OF MEDICAL EDUCATION PROGRAM*,**
*“Consensus Commission Report” based on draft compiled at “Workshop for Revision of
Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of
Medicine”
**© 2011, Yeditepe University Faculty of Medicine
AIMS
The aim of medical education program is to graduate physicians who

are aware of the local and global health issues

have acquired competence in knowledge, skills and attitudes to manage and provide
primary health care service

know, apply and care for ethical principles of the medical profession

keep up with current knowledge at national and international level

are capable of systematical thinking

are investigative and questioning

continually renovate and improve themselves

are capable of teamwork

use technology competently in medicine and related areas

have effective communication skills

have community leadership qualifications
1
OUTCOMES
Graduate should be able to:
1) practice as a physician,
 oriented towards
o individual and non-individual factors affecting health
o sustainment and improvement of healthy condition
o clinical conditions which
o are frequent in community
and/or
o pose high risk for individual or community health
and/or
o life-threatening or constitute an emergency
 at a competency level appropriate to deliver primary health care services compatible with
surrounding context of health determinants.
1.1. explain normal structural components of human body, their functions and operational
mechanisms at organismal, multisystem, system, organ, tissue, cellular and molecular levels.
1.2. explain healthy condition and factors affecting health.
1.3. explain and relates causes of clinical conditions, courses of effect and outcomes.
1.4. explain changes (i.e. physiological and pathological) in structural components of body, their
functions and operational mechanisms under healthy and clinical conditions.
1.5. explain most frequently occurring or most important clinical complaints (i.e. chief complaint),
symptoms, signs, laboratory and imaging findings and their emergence mechanisms in
clinical conditions.
1.6. explain current medical and surgical methods used in interventions directed towards health
conditions.
1.7. use contextually appropriate medical history taking method, out of different types (e.g.
comprehensive, focused or hypothetico-deductive) and systematically, to gather medical
information from healthy individual, patient or patient’s companions (i.e. heteroanamnesis),
in case of an encounter with a healthy person or a patient who seeks health care service for
a health condition.
1.8. employ physical examination methods for systems in case of an encounter with a healthy
person or a patient who seeks health care service for a health condition.
1.9. accurately interpret findings in medical history and physical examination, in case of an
encounter with a healthy person or a patient who seeks health care service for a health
condition.
1.10. implement diagnostic procedures (e.g. point of care testing, physician office testing)
required for primary health care, in case of an encounter with a healthy person or a patient
who seeks health care service for a health condition.
1.11. select (utilize) tests shown to be highly effective in clinical decision making by evidencebased medicine from the aspects of reliability, practicality and outcome measures, in case of
an encounter with a healthy person or a patient who seeks health care service for a health
condition, and interpret results.
1.12. make clinical decisions (e.g. benefit estimation, risk estimation, prevention, screening, test
requisition, diagnosis, triage, staging, consultation, prognosis, watchful-waiting, intervention,
monitoring, end of intervention, discharge, control, end of follow-up) shown to be highly
effective from the aspects of outcome measures by evidence-based medicine, in case of an
encounter with a healthy person or a patient who seeks health care service for a health
condition.
1.13. accurately perform interventional procedures (i.e. interventional clinical skills,
competencies and proficiencies) required for primary health care, in case of an encounter
with a healthy person or a patient who seeks health care service for a clinical condition.
1.14. coordinate referral or transport of patient, when necessary and with patient-centered
approach, to secondary health care institution, without posing any risk to patient’s health,
security and confidentiality, in case of an encounter with a patient who seeks health care
service for a clinical condition.
2
1.15. manage request or symptom, healthy or clinical condition, and healthy individual or patient,
with beneficiary-centered approach, and with clinical decisions made by analytical and critical
thinking, clinical reasoning and problem solving methods, in case of an encounter with a
patient who seeks health care service for a health condition.
1.16. execute protective and therapeutic medical practices that are individual, family and
community-oriented, easily accessible, integrated and coordinated, continuous,
comprehensive, and based on the principles of confidentiality, in primary health care services.
1.17. identify factors that pose a high risk to individual and community health, and determine
individuals or populations at risk in advance or at an early stage and implement the necessary
measures.
1.18. value preventive health services, offer primary prevention (i.e. prevention of diseases
for the protection of health), secondary prevention (i.e. early diagnosis and treatment) and
tertiary prevention (i.e. rehabilitation) services, and provide consultacy on these issues.
1.19. provide life-style consultancy and design services to sustain and improve individual and
community health.
2) manage primary health care services.
2.1. manage health care team in primary health care organization.
2.2. lead community with sense of responsibility, good behavior and manners in consideration of
individual behaviors and social dynamics of community, and if there is a necessity, develop
projects directed towards health care services.
2.3. define health management and economics principles, models for organization and finance of
health care services.
2.4. use health care resources with cost-effective manners.
3) advocate individual and community health under all circumstances.
3.1. provide consultancy services to sustain and promote the health of individual and community.
3.2. explain epidemiology of clinical conditions, and define measures to reduce frequencies.
3.3. describe completely all high risk factors for the community health (e.g. natural disasters, nuclear
accidents, fire, war, bio-terrorism, etc.), and implement necessary measures in order to prevent
effects on health.
3.4. explain health determinants completely (e.g. physical environment, social environment, genetic
background, individual response -behavior, biology-, health care services, welfare, etc.), including
conditions that prevent access to health care.
4) perform medical practices according to regulatory and ethical principles and in consideration
of behavioral sciences, social sciences, and humanities.
4.1. recognize determinants affecting individual behaviors and attitudes, and social dynamics.
4.2. recognize basic ethical principles completely, and distinguish ethical and legal problems.
4.3. recognize regulations concerning national and international health systems.
4.4. employ safety, security and confidentiality principles completely for beneficiaries of health care
services, companions and visitors, and health care workers.
4.5. use medical record and information systems according to regulations and ethical principles.
4.6. value informed consent taking in the framework of patients’ rights, and employ fully.
4.7. interpret historical, anthropological and philosophical evolution of medicine, health and disease
concepts, and relate to current medical practice.
5) establish correct and effective communication with all stakeholders of health care services
and collaborate.
5.1. communicate by using problem solving abilities during all of professional life with health care
beneficiaries, co-workers, accompanying persons, visitors, patient’s relatives, care givers,
colleagues, other individuals and organizations.
5.2. collaborate with related organizations and institutions, with other professionals and health care
workers as a team member through using problem solving abilities.
5.3. communicate with all stakeholders with consideration of socio-cultural differences.
3
6) promote self medical knowledge and skills in view of the current scientific developments
throughout own career.
6.1. adopt and implement the importance of lifelong self-learning.
6.2. recognize importance of updating knowledge and skills; search current advancements and
improve own knowledge and skills.
6.3. speak at least one foreign language at advanced level to follow the international literature and
communicate with colleagues.
6.4. recognize methods to reach current scientific knowledge, and use available technology.
6.5. recognize principles of evidence-based medicine, and implement in health care services.
6.6. develop and present research projects.
7) manage own postgraduate career.
7.1. recognize and investigate postgraduate work domains and job opportunities.
7.2. determine postgraduate work domains, job opportunities and requirements for application,
distinguish and plan requirements for further training and work experience.
7.3. prepare a resume, and recognize job interview methods.
7.4. recognize health technologies expected to be implemented in near future and emerging work
areas.
4
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
COORDINATION COMMITTEE
(TEACHING YEAR 2014 – 2015)
Gülderen Yanıkkaya Demirel, MD, Assoc.Prof.(Coordinator)
Özlem Tanrıöver, MD, Assoc. Prof. (Co-coordinator)
Ayşegül Kuşkucu, MD, Assist.Prof. (Co-coordinator)
Elif Vatanoğlu, MD, Assist.Prof. (Co-coordinator)
Mehtap Kaçar, MD, Assist.Prof. (Co-coordinator)
ICP III COORDINATION COMMITTEE
Özlem Tanrıöver, MD, Assoc.Prof (Coordinator)
Ayşe Arzu Akalın, MD Assist.Prof. (Co-coordinator)
Turhan Özler, MD, Assist. Prof. (Co-coordinator)
5
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
DESCRIPTION OF THE PHASE
Physiopathological process and pathological process.
PHASE CONTENT
Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System,
Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry,
Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.
EXECUTIVES OF ACADEMIC YEAR
Emergency Medine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics,
Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology,
Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology,
Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology,
Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology,
Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology,
Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical
Education
6
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
AIMS and LEARNING OBJECTIVES of PHASE III
AIMS OF PHASE III
In evidence based manner ;
1.
2.
3.
3.1.
3.2.
3.3.
3.4.
4.
5.
6.
7.
8.
to remind anatomy, histology and physiology of body systems,
to convey necessary knowledge, related to body systems, on prevention of clinical conditions’
emergence, protection and improvement of health in healthy conditions.
at multi-system level or related to a body system, for clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency;
to convey necessary knowledge on risk factors, etiopathogenesis, physiopathology, and
pathology,
to convey knowledge on epidemiology,
to convey knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
to convey necessary knowledge on health care processes, clinical decision making process,
clinical decisions and clinical practices, with performance measures, for managing at the level of
primary health care service,
to convey knowledge on pharmacology of drugs that are effective at multi-system level, specifically
on a body system or on clinical conditions involving a specific body system,
to convey knowledge on phytotherapeutic agents that are effective at multi-system level,
specifically on a body system or on clinical conditions involving a specific body system,
to convey knowledge on biostatistical analysis,
to convey basic legal and ethical principles that should be followed in practice of medical
profession,
to equip with basic and advanced professional and clinical (interventional or non-interventional)
skills necessary for practice of medical profession.
7
LEARNING OBJECTIVES OF PHASE III
At the end of this phase, student should be able to:
1.0. recall anatomy, histology and physiology of body systems.
2.0. list necessities for prevention of clinical conditions’ emergence, protection and improvement of
health in healthy conditions in relation to body systems.
3.0. explain risk factors and etiopathogenesis, at multi-system level or related to a body system, of
clinical conditions which are frequent in community and/or pose high risk for individual or community
health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. recognize morphological characteristics,
4.2. show basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency;
5.1. explain mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and
organismal level,
5.2. describe structural and functional changes caused,
5.3. list clinical courses in time.
6.0. explain mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,
•
for healthy conditions in an individual or community with a request, or
•
in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
•
for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and with performance measures from the aspects of
reliability, practicality and outcomes,
•
health care processes,
•
acquisition of subjective or objective data, information and knowledge required for clinical
decision making,
•
clinical decision making process,
•
clinical decisions and
•
clinical practices
which are required for management at primary health care service level.
7.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2,
gastrointestinal-C4,
gynecological-C5,
breast-C5,
neonatal,
prepubertal/pubertal-C6,
neurological/neuropsychiatric-C7, musculoskeletal-C8)
7.2. evaluation of emergency case (sepsis and septic shock-C1, dyspnea-C2, acute abdominal painC4, urological emergencies-C6, neurological emergencies-C7, trauma-C8)
7.3. approach to healthy individual or patient (fever-C1, cardiovascular disease-C2, chest pain-C2,
cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4,
pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depressionC7, dementia-C7, musculoskeletal dysfunction-C8)
7.4. laboratory and imaging tests/examinations
7.4.1. based on laboratory disciplines/subdisciplines;
1.
medical biochemistry tests:
i.
(venous blood collection-C5)
ii.
(thyroid function tests-C5, diabetes tests-C5)
2.
medical microbiology tests:
i.
(urine sample collection-C1, throat swab specimen-C5, sputum sample
collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal
specimen collection-C6, wound sample collection-,blood collection for culture-)
8
ii.
(urine
strip/dipstick
test-C1,
urine
culture-C1,
rapid
screening
(antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethralvaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood
culture-)
3.
medical pathology tests:
i.
(C2, C4, C6, C7, C8, Pap smear collection)
ii.
(C2, C4, C6, C7, C8, Pap smear)
4.
other laboratory tests:
i.
(peripheral/venous blood collection for hematology tests-C3, blood sample
collection for therapeutic drug monitoring-C8)
ii.
(pulmonary function tests-C2, hematology tests for anemia-C3, monitarization
of drug therapy-C8)
7.4.2. imaging tests/examinations based on disciplines/subdisciplines:
5.
radiological examinations: (radiological examinations in gynecology-C5, breast
imaging-C5, uroradiology-C6, conventional neuroradiological examinationsC7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological
imaging of musculoskeletal system-C8, radiological examinations in benign ve
malign tumors of bones-C8)
6.
nuclear medicine examinations: (nuclear medicine tests in infectious diseasesC1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac
PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2, nuclear
medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in
gastrointestinal system tumors-C4, radioisotope imaging of thyroid and
parathyroid-C5, renal scintigrahy (GFR, ERPF, Renogram)-C6, brain perfusion
scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)
7.4.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1.
medical biochemistry tests: (diabetes tests-C5, cardiac markers-, coagulation
tests-, blood gases-).
2.
medical microbiology tests: (urine strip/dipstick test-C1, rapid screening
(antigen/antibody tests-C5)
3.
other laboratory testsi: (hematology-peripheral blood smear examination-C3,
hematology-complete blood count-)
7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. practicing non-intervention or intervention
7.8. referral/transport of healthy individual or patient
9
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
ACADEMIC CALENDAR 2014 - 2015
COMMITTEE I
INFECTIOUS DISEASES
(4 WEEKS)
Beginning of Committee
End of Committee
Committee Exam
September 08, 2014
October 01, 2014
October 02, 2014
Coordination Committee Meeting
Religious Holiday
September 29, 2014
October 03-07, 2014
Monday
Wednesday
Thursday
Monday
Friday-Tuesday
COMMITTEE II
CARDIOLOGY AND RESPIRATORY SYSTEM
Beginning of Committee
October 08, 2014
End of Committee
November 21, 2014
Committee Exam
November 28, 2014
(8 WEEKS)
Wednesday
Friday
Friday
Republic Day
Commemoration of Atatürk
October 28-29, 2014
November 10, 2014
Tuesday-Wednesday
Monday
COMMITTEE III
HEMATOPOIETIC SYSTEM
Beginning of Committee
December 01, 2014
(3 WEEKS)
Monday
End of Committee
December 15, 2014
Monday
Committee Exam
December 19, 2014
Friday
COMMITTEE IV
(4 WEEKS)
GASTROINTESTINAL SYSTEM
Beginning of Committee
End of Committee
Committee Exam
OSCE I (Exam)
December 22, 2014
January 09, 2015
January 15, 2015
January 16, 2015
Monday
Friday
Thursday
Friday
New Year
Coordination Committee Meeting
MIDTERM BREAK
Make-up Exam I
January 1, 2015
January 5, 2015
January 19, 2015
February 09, 2015
Thursday
Monday
January 30, 2015
Monday
10
COMMITTEE V
ENDOCRINE SYSTEM & REPRODUCTIVE SYSTEM
Beginning of Committee
February 02, 2015
End of Committee
February 24, 2015
Committee Exam
February 27, 2015
(4 WEEKS)
Monday
Tuesday
Friday
COMMITTEE VI
URINARY SYSTEM
Beginning of Committee
End of Committee
Committee Exam
March 02, 2015
March 19, 2015
March 27, 2015
(4 WEEKS)
Monday
Thursday
Friday
Physicians’ Day
March 14, 2014
Saturday
COMMITTEE VII
NERVOUS SYSTEM & PSYCHIATRY
Beginning of Committee
March 30, 2015
End of Committee
April 30, 2015
Committee Exam
May 08, 2015
National Sovereignty and
Children's Day
Coordination Committee Meeting
Labor’s Day
COMMITTEE VIII
MUSCULOSKELETAL SYSTEM
Beginning of Committee
End of Committee
Committee Exam
OSCE II (Exam)
(6 WEEKS)
Monday
Friday
Friday
April 23, 2015
Thursday
April 27, 2015
May 1, 2015
Monday
Friday
May 11, 2015
June 01, 2015
June 05, 2015
June 08, 2015
(4 WEEKS)
Monday
Friday
Friday
Monday
National Holiday
May 18-19,2015
Coordination Committee Meeting July 01, 2015
Monday-Tuesday
Wednesday
Make-up Exam I
Make-up Exam II
OSCE I (Exam)
OSCE II (Exam)
February 09, 2015
June 15, 2015
January 16, 2015
June 08, 2015
Monday
Monday
Final Exam
Incomplete Exam
June 29, 2015
July 24, 2015
Monday
11
Friday
Monday
Friday
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
STUDENT COUNSELING
Student counseling is a structured development process established between the student and the
consultant that aims to maximize student success by focusing the student to her/his target. Although the
major component of this relationship is the student, the faculties also take part by bringing the
requirements of this interaction to their systems. The targeted outcomes of the consultant-student
interaction are success in the exams, success in the program, and preparation for the professional life.
The aim of counseling is to help students to solve their problems, to give professional guidance, to
provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about
the University and Faculty, to follow their success and failure and to help them select courses.
The consultants selected among Basic Medical Sciences instructors for the first three years transfer the
students to Clinical Sciences instructors for the following three years.
The topics that will be addressed by the consultants are as follows:
a. Inform students about the university, faculty and surrounding facilities
b. Inform students about the courses and help them select courses
c.
Inform students about the education and assessment regulations
d. Follow students attendance to lectures and success
e. In case of failure, investigate the causes and cooperate with the students to overcome them
f.
Help students in career planning
g. Contribute to students adapting the habit of lifelong learning
h. Guide students to counseling services of the university
i.
Set a role model as long as the professional susceptibility, professional guidance, intellectual
responsibility, interaction with peers, ethics, professional values are concerned
j.
Contribute to cultivation of professional and intellectual development in a rapidly changing world
k.
Inform the coordinator when there are unsolved problems of the students
Consultant-student relationship is a dynamic and mutual process carried out within the campus and the
hospital. It is recommended that the consultant and the student meet at least twice during a semester.
The expectations from the student are as follows:
a) Contribute to improvement of satisfaction level in the problem areas
b) Report the social and economic conditions that require consultant’s help
c) Specify expectations from the education and the department from which this training is taken
d) Give feedback on the counseling services regarding their satisfaction level
12
LIST OF STUDENT COUNSELING
PHASE III
NECAT İREM
ABDULHAYOĞLU
DR. ÜNAL USLU
ECE MELİS
ADALET
DR. ÜNAL USLU
DUYGU
ADIBELLİ
DR. ÜNAL USLU
GÖZDE
AKAN
DR. DENİZ KIRAÇ
MEHMET
AKAN
DR. DENİZ KIRAÇ
MEHMET
AŞTI
DR. DENİZ KIRAÇ
HASAN BERKE
ATALAY
DR. ÇİĞDEM KASPAR
HASAN BERK
BARIŞCIL
DR. ÇİĞDEM KASPAR
İREM
BAŞARAN
DR. BAYRAM YILMAZ
ELİF
BAYRAKTAR
DR. BAYRAM YILMAZ
GÖKTUĞ
BORA
DR. KAAN YÜCEL
OZAN
CENGİZ
DR. KAAN YÜCEL
NUR BÜKE
ÇABUK
DR GÜLDEN ÇELİK
HARİKA
ÇAĞLAYAN
DR GÜLDEN ÇELİK
AYLİN
ÇETİNKAYA
DR. AKİF MAHARRAMOV
ECE NUR
ÇINAR
DR. AKİF MAHARRAMOV
FATMA BEGÜM
ÇOPUR
DR. AKİF MAHARRAMOV
GAMZE BİLGE
DALGIN
DR GÜLDEN ÇELİK
CEREN
DALKIRAN
DR. TURGAY İSBİR
BURAK
DEMİRCİ
DR. TURGAY İSBİR
ZEYNEP
DEMİRCİ
DR. TURGAY İSBİR
ALPER
DÜNKİ
DR. ELİF VATANOĞLU
EZGİ
ERDAĞ
DR. ELİF VATANOĞLU
CİHAD
ERİM
DR. ELİF VATANOĞLU
EZEL
GEDİK
DR. YEŞİM GÜROL
MÜGE
GÜLER
DR. YEŞİM GÜROL
ECE EMİNE
GÜMÜŞKESEN
DR. YEŞİM GÜROL
GİZEM
GÜRBÜZ
DR. YEŞİM GÜROL
MERVE
GÜRKÖK
DR. ÇAĞATAY ACUNER
BERK
GÜRSOY
DR. ÇAĞATAY ACUNER
MERT
GÜRSOY
DR. ÇAĞATAY ACUNER
DİLAN
HAKYERİ
DR. ÇAĞATAY ACUNER
ZEYNEP
HÜSEYİNOĞLU
DR. BURCU ŞEKER
ZEYNEPGÜL
İNKAYA
DR. BURCU ŞEKER
MUSTAFA BEYKAN
İSTANBULLU
DR. ALEV CUMBUL
UĞUR KAAN
KALEM
DR. ALEV CUMBUL
RANA SELİN
KARAMAN
DR. ALEV CUMBUL
SEVİM PIRIL
KARASU
DR. ALEV CUMBUL
DENİZ
KAVGACI
DR. ALEV CUMBUL
REBECCA
KELLER
DR. ÖZLEM TANRIÖVER
İBRAHİM UMUR
KEPSUTLU
DR. ÖZLEM TANRIÖVER
13
ARTUN
KIRKER
DR. ÖZLEM TANRIÖVER
DOĞUŞ
KÖKARTTI
DR. HÜLYA AKAN
FATİH
KÖKDERE
DR. HÜLYA AKAN
AHMET ENES
KÜÇÜKARDALI
DR. HÜLYA AKAN
BASEL
EL MASRİ
DR. HÜLYA AKAN
ÖZNUR
MOLLA
DR. İNCİ ÖZDEN
EMİRHAN
NAS
DR. İNCİ ÖZDEN
FATEMEH
MOHAMMADI NASER
DR. İNCİ ÖZDEN
MÜGE
ORAL
DR. JALE ÇOBAN
MUSTAFA FATİH
ÖĞÜNÇLÜ
DR. JALE ÇOBAN
PIRILTI
ÖZCAN
DR. JALE ÇOBAN
MAHMUT ESAT
ÖZCAN
DR. JALE ÇOBAN
ESİN
ÖZÇELEBİ
DR. ARZU AKALIN
PINAR
ÖZEN
DR. ARZU AKALIN
BEYZA
ÖZER
DR. ARZU AKALIN
AYBERK
ÖZKAVAKLI
DR. ARZU AKALIN
BESTE
ÖZTÜRK
DR. ECE GENÇ
NEVA
ÖZTÜRKER
DR. ECE GENÇ
BAHAR
PEZÜKLİ
DR. ECE GENÇ
VIOLA
RIGOTTİ
DR. FERDA KALEAĞASIOĞLU
ONUR
SÖKÜCÜ
DR. FERDA KALEAĞASIOĞLU
CEM
ŞAKAR
DR. AYŞEGÜL KUŞKUCU
UĞUR
ŞEN
DR. AYŞEGÜL KUŞKUCU
ENVER
ŞENBAYRAM
DR. AYŞEGÜL KUŞKUCU
EMİR
ŞENOCAK
DR. AYŞEGÜL KUŞKUCU
RECEP
TEMEL
DR. FERDA ÖZKAN
ORHUN UFUK
TİPİ
DR. FERDA ÖZKAN
AHMET FATİH
USLU
DR. IŞIN DOĞAN EKİCİ
BERFİN GİZEM
USLU
DR. IŞIN DOĞAN EKİCİ
RAGİBE BÜŞRA
USTA
DR. IŞIN DOĞAN EKİCİ
MERİÇ
ÜLGEN
DR. IŞIN DOĞAN EKİCİ
FATMA TUĞÇE
YAVUZ
DR. GÜLDEREN YANIKKAYA DEMİREL
EYLÜL
YERAL
DR. GÜLDEREN YANIKKAYA DEMİREL
ASLI DENİZ
YERLİKAYA
DR. ÇAĞATAY ACUNER
MEHMET İSKENDER
YILDIRIM
DR. GÜLDEREN YANIKKAYA DEMİREL
CEMRE
YILMAZ
DR. GÜLDEREN YANIKKAYA DEMİREL
HAZAL
YILDIZ
DR. SONER DOĞAN
MUSTAFA FADIL
YUNIS
DR. SONER DOĞAN
FATMA PINAR
ZİYADANOĞLU
DR. SONER DOĞAN
BURHAN
ZORLU
DR. SONER DOĞAN
14
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
ASSESSMENTS
Assessments table will be made with consideration of each learning objective for each
committee and will be announced and explained in introductory lectures at the
beginning of the committee.
EXAMINATION MATRIX
MD 320 Introduction to Clinical Sciences
Assessment Modalities



WE: Written (Theoretical) Exams
o MCQ: Multiple Choice Questions.
o EMQ: Extended Match Questions.
PE: Practical Exams
o OSCE: Objective Structured Clinical Exam*
SP: Scientific Projects (Assessment will be based on project proposals written by
students)
*A form of performance-based testing used to measure a student’s clinical competence. During an
OSCE, students are observed and evaluated as they go through a series of stations in which they
interview, examine and treat standardized patients who present with some type of medical problem.
Written (Theoretical) Exams (WE)



Committee Exams (CE)
o Number of Questions: 100
o Question Types: 10% EMQ**, 90% MCQ
Final Exam (FE)
o Question Number: 200
o Question Types: 100% MCQ
Incomplete Exam (IC)
o Question Number: 100
o Question Type: 100% MCQ
**Percentage that will be reflected in total points of exam. Does not correspond to the exact number of
questions.
Term Score (Pass or Fail) Calculation***:

Term Score=(60% of CE Average) + (40% of Final Score or Incomplete Score)
o Final Score= (OSCE1 5%) + (OSCE2 5%) + (SP 4%) + (FE 86%)
o Incomplete Score= (OSCE1 5%) + (OSCE2 5%)+(SP 4%) + (IC 86%)
***Fail: FE<50 or Term Score<50

Pass: Term Score>50
The distribution of questions in the question distribution tables in all exams
could be changed by the coordinators.
15
What is OSCE?
The objective structured clinical examination (OSCE) is a proven valid and reliable, used both for
formative and summative tool for assessing the clinical skills of medical students (1-3).
OSCE is a type of performance-based examination used to measure a student’s clinical
competence. During an OSCE, students are observed and evaluated in which they interview, examine
and write prescriptions to standardized patients who present with a medical problem.
What is the infrastructure of your laboratory?
We have three examination room designed as doctors office which are monitored by 360 degrees
cameras, we have an observer room with a one sided mirror and a control room equipped with
computers and monitoring stations.
How is the performance evaluated?
Monitored exam rooms are used for taking a history from a standardized patient, performing a physical
examination or diagnostic procedure, or teaching/counseling/advising a patient. A rating form or
standardized checklist is used for the evaluation criteria.
A student is asked to answer questions, write a report or a prescription, or interpret findings such as lab
reports and X-rays. The types of problems portrayed in an OSCE are those students would commonly
see in a clinic or hospital. OSCE stations are mostly planned clinical encounters in which a student
interacts with a standardized patient (SP). Evaluation criteria are based on course objectives and
student learning activities.
References:
1. Harden RM, Gleeson FA. Assessment of clinical competence using an objective structured
clinical examination (OSCE). Med Educ 1979;13:41–5.
2. Cohen R, Reznick RK, Taylor BR, Provan J, Rothman A. Reliability and validity of the objective
structured clinical examination in assessing surgical residents. Am J Surg. 1990; 160:302-5.
3. Newble DI. Assessing clinical competence at the undergraduate level. Med Educ. 1992; 26:50411.
16
Yeditepe University Faculty of Medicine Exam Rules







Seating- Students will be seated by the exam observers or proctors. Students are not allowed to
change their seats without permission.
Electronics – During examinations or tests, students are prohibited from using electronic devices
or any other means of communication and recording that have not been approved beforehand. All
electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged
with academic fraud.
Absence – No additional time will be given to students who are absent for part of the exam,
regardless of the reason for their absence.
Scratch Paper – Students are not allowed to bring scratch paper into the exam room.
Meaning of Questions – Students may not consult the supervisor as to the meaning of any
question.
Sign your sheets – Students must sign their multiple-choice answer sheets and/or written-answer
sheets.
Other activities requiring disciplinary action- Students must not give or receive assistance of
any kind during the exam. Gaining access to exam questions before the exam; • Using an
unauthorized calculator or other mechanical aid that is not permitted. • Looking in the exam book
before the signal to begin is given. • Marking or otherwise writing on the exam book or answer sheet
before the signal to begin is given. • Making any changes, additions, deletions or other marking,
erasing or writing on the exam book or answer sheet after the time for the exam has expired. •
Having access to or consulting notes or books during the exam. • Looking at or copying from another
student’s paper. • Enabling another student to copy from one’s paper. • Talking or otherwise
communicating with another student during the exam or during the read through period. • Disturbing
other students during the exam. • Consulting other persons or resources outside the exam room
during the exam. • Copying questions or answers either on paper or with an electronic device to
take from the exam room. • Taking an exam book or other exam materials from the exam room. •
Taking an exam in place of another student. • Arranging to have another person take an exam for
the student. • Threatening or verbally abusing a supervisor or proctor responsible for curbing or
reporting improper conduct. • Unprofessional and/or unruly behavior towards any Yeditepe
University staff, supervisors, proctors, or volunteers at any time. • Disclosing the contents of an
exam to any other person. • Failing to remain in the exam room for a given period of time by the
supervisors or proctors. • Failing to follow other exam instructions.
Students who assist in or are complicit with cheating could also be in violation of the Policy. Thus,
students who become aware of their peers either facilitating academic misconduct or committing it
should report their suspicions to exam or test observers for investigation.
Those students found to have committed academic misconduct will face administrative sanctions
imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary
rules and regulations of the Turkish Higher Education Council (YÖK) for students: published in the
Official Gazette on August 18th, 2012). The standard administrative sanctions include: the creation of
a disciplinary record which will be checked by graduate and professional life, result in grade “F” on the
assignment, exams or tests or in the class. Students may face suspension and dismissal from the
Yeditepe University for up to one school year. In addition, student may loose any academic and non
academic scholarships given by the Yeditepe University for up to four years. The appropriate sanctions
are determined by the Yeditepe University administration according to egregiousness of the Policy
violation.
17
SCIENTIFIC PROJECTS
The aim of Scientific Projects program is to develop awareness in medical students for the importance
of scientific projects in profession and provide them opportunity to gain knowledge, skills and attitudes
in writing and conducting a scientific project. Throughout the year, each Phase Three student is
expected to prepare a scientific project proposal. Students are free to choose their research area and
advisor for their prospective research project. Students who wish to apply for a “TUBITAK 2209-A
National Grant Program for University Students” has to send in their proposals before February 2015,
the rest should hand in their proposals before the end of March. Scientific Projects have four (4) points
contribution to final exam results, evaluation scale for projects is as follows:
CRITERIA
Is the question/
problem presented
clearly?
Creativity/originality
of the Project
Is set up of the
Project suitable to
obtain aims?
Presentation of aims
in an easy to
understand format
Review of project
proposal in light of
literature
Proposal presentation
in correct format
Does proposal
explain the project’s
significance and
contributions well?
Project calendar
presentation
TOTAL POINTS
EVALUATION POINTS
Very Good
Good
Acceptable
Weak
Bad
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
0.5
0.4
0.3
0.2
0.1
4.0
18
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
INFECTIOUS DISEASES
COMMITTEE I
DISTRIBUTION of LECTURE HOURS
September 08, 2014 – October 02, 2014
COMMITTEE DURATION: 4 WEEKS
DISCIPLINE
 INFECTIOUS DISEASES
AND CLINICAL
MICROBIOLOGY
 PHARMACOLOGY
ABBR.
THEO.
IDCM
16
PC
15
15
PATHOLOGY
PT
8
8
8
8
BED
8
8

PUBLIC HEALTH
BIOMEDICAL ETHICS &
DEONTOLOGY
CLINICAL SKILLS
LABORATORY
BIOSTATISTICS
PH

INTERNAL MEDICINE





PRAC.
LAB/CSL
DISCUSSION TOTAL
2
(4 Groups)
18
3
(4 Groups)
CSL
3
BS
2
IM
2
2
PATHOPHYSIOLOGY
PP
2
2

FAMILY MEDICINE
FM
2
2

MEDICAL GENETICS
MG
2
2

EMERGENCY MEDICINE
EM
1
1

PEDIATRICS
PED
1
1

SCIENTIFIC PROJECTS-III
SP
1
1
TOTAL
68
2
5
Coordination Committee
HEAD
Gülden Çelik MD Prof
SECRETARY
Yeşim Gürol, MD Assoc. Prof
Meral Sönmezoğlu, MD Assoc. Prof
Sezgin Sarıkaya, MD Assoc. Prof
Ayşegül Ç. Kuşkucu, MD PhD Assist Prof
(Co-coordinator)
MEMBER
MEMBER
MEMBER
19
2
4
75
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
INFECTIOUS DISEASES
LECTURERS
DISCIPLINE
INFECTIOUS DISEASES AND
CLINICAL MICROBIOLOGY
INTERNAL MEDICINE
PHARMACOLOGY
PATHOLOGY
PATHOPHYSIOLOGY
LECTURERS
Gülden Çelik, MD Prof.
Meral Sönmezoğlu, MD Assoc. Prof.
Yeşim Gürol, MD Assoc. Prof.
İ. Çağatay Acuner, MD Assoc Prof.
Yaşar Küçükardalı, MD. Prof.
Ece Genç, PhD Prof.
Ferda Kaleağasıoğlu, MD, Assoc.Prof.
Ferda Özkan, MD Prof.
Işın Doğan Ekici, MD Assoc. Prof.
Mehtap Kaçar, MD PhD Assist. Prof.
CLINICAL SKILLS LAB
Erol Sezer, MD Prof
Hale Arık Taşyıkan, MD Assist Prof
Güldal İzbırak, MD Assoc.Prof.
Özlem Tanrıöver, MD Assoc.Prof.
Sezgin Sarıkaya, MD Assoc. Prof.
EMERGENCY MEDICINE
Sezgin Sarıkaya, MD Assoc. Prof.
BIOMEDICAL ETHICS &
Elif Vatanoğlu, MD Assist. Prof.
PUBLIC HEALTH
FAMILY MEDICINE
DEONTOLOGY
BIOISTATISTICS
Çiğdem Kaspar, PhD Assist. Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
SCIENTIFIC PROJECTS-III
Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.
20
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
INFECTIOUS DISEASES
COMMITTEE I
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on structures of agents that cause infectious clinical conditions which are
frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency,
2. to convey knowledge on epidemiology of infectious clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency,
3. to convey knowledge on pathogenesis mechanisms of agents that cause infectious clinical
conditions which are frequent in community and/or pose high risk for individual or community health,
and/or life-threatening or constitute an emergency,
4. to convey necessary knowledge on prevention of infectious clinical conditions, and protection or
improvement of health against these conditions,
5. to convey knowledge on mechanisms of occurrence for frequently encountered clinical complaints,
symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. to convey necessary knowledge together with performance measures on health care processes,
clinical decision making process, clinical decisions and clinical practices required for managing
infectious clinical conditions, which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency, at the level of primary health
care service,
7. to convey necessary knowledge on pharmacology of drugs used in infectious clinical conditions
which are frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency,
8. to convey necessary knowledge on ethical problems encountered in health care service and
utilization, and on principles of solutions,
9. to convey biostatistical knowledge required in design of medical research,
10. to convey basic knowledge on phytotherapy,
11. to convey necessary knowledge on genetical basis of clinical conditions,
12. to equip with basic clinical skills, (intravenous injection on phantom model), required at primary
health care service level.
21
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.0. explain basic characteristics of infectious clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency,
2.1. recall structures, and
2.2. explain mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that
cause infectious clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency,
3.0. classify infectious clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency, based on
causative agents and systems,
4.0. explain mechanisms of change in structure and function at molecular, cellular, tissue, system, multisystem and organismal levels in infectious clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency,
5.0. explain mechanisms of host immune response to and consequences in infectious clinical conditions
which are frequent in community and/or pose high risk for individual or community health, and/or
life-threatening or constitute an emergency,
6.0. explain epidemiology of infectious clinical conditions which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency,
7.0. explain requirements for prevention of infectious clinical conditions, and protection or improvement
of health against these conditions, in healthy or susceptible individual or community,
8.0. explain mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs
and findings in infectious clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency,
9.0. at multi-system level or related to a body system,
• for healthy conditions in an individual or community with a request against infectious clinical
conditions that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for infectious clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects
of reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
9.1. practice of history taking and physical examination
9.2. evaluation of emergency case (sepsis and septic shock-C1)
9.3. approach to healthy individual or patient (fever-C1)
9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine cultureC1)
9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)
9.6. point of care testing (urine strip/dipstick test-C1)
9.7. making preliminary diagnosis or definitive diagnosis decision
9.8. making non-intervention or intervention decision
9.9. practicing non-intervention or intervention
9.10. referral/transport of healthy individual or patient
10.1.list goals and principles of drug use,
10.2.describe effects,
10.3.explain mechanism of action (pharmacodynamics),
10.4.list indications, contraindications, pharmacological features, pharmacokinetic characteristics,
drug-drug inreactions and side effects,
10.5.explain resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial,
antifungal, antiviral, antiprotozoal, antimalarial, antihelmintic drugs, antiseptics and disinfectants)
used in infectious clinical conditions,
22
11.0. explain interactions of health conditions (healthy and clinical conditions) at individual, family and
community levels in relation to infectious agents, and importance of infectious agents and infectious
clinical conditions from the aspect of public health,
12.0.define approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening,
surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious
clinical conditions which are frequent in community and/or pose high risk for individual or community
health,
14.0. explain hereditary immune system disorders,
15.0.explain ethical problems (violation of truthfulness, responsibilities of physician and patient,
allocation of scarce resources) encountered in health care service and utilization, and principles of
solutions,
16.0. define biostatistical knowledge required in design of medical research (research design, planning
medical research,
17.0. explain basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine,
regulations, standardization and quality control),
18.0. perform basic clinical skills, practiced on phantom models (intravenous injection-C1), required at
primary health care service level.
15.0.explain ethical problems (violation of truthfulness, responsibilities of physician and patient,
allocation of scarce resources) encountered in health care service and utilization, and principles of
solutions,
16.0. define biostatistical knowledge required in design of medical research (research design, planning
medical research,
17.0. explain basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine,
regulations, standardization and quality control),
18.0. perform basic clinical skills, practiced on phantom models (intravenous injection-C1), required at
primary health care service level.
23
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE I
INFECTIOUS DISEASES
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0, 2.0.,3.0. (4.0.-12.0.)
1.0.,3.0. (4.0.-12.0.)
4.0.,5.0.
4.0.,5.0.
4.0.,5.0.,8.0.
6.0.,7.0.,11.0.,12.0.
6.0.,7.0.,11.0.,12.0.
8.0.,9.0., 9.1.
9.2.
9.3. (6.0.-9.0.,11.0.,12.0.)
9.3. (6.0.-9.0.,11.0.,12.0.)
9.4.
10.0.
10.0.
14.0.
15.0.
16.0.
FACULTY
DEPARTMENT
IDCM
IDCM
PT
PT
PP
PH
PH
IM
EM
FM
FM
IDCM
PC
PC
MG
BED
BS
LECTURER/INSTRUCTOR
Y. Gürol
M. Sönmezoğlu
F. Özkan
I. D. Ekici
M. Kaçar
R.E. Sezer
H.A.Taşyıkan
Y. Küçükardalı
S. Sarıkaya
Ö. Tanrıöver
G. İzbırak
G. Çelik
E. Genç
F. Kaleağasıoğlu
A. Ç. Kuskucu
E. Vatanoğlu
Ç. Kaspar
TOTAL
LEARNING OBJECTIVE
FACULTY
DEPARTMENT
1.0, 2.0.,3.0. (4.0.-12.0.)
IDCM
10.0.
4.0.,5.0.
PC
PT
CE
3
10
5
5
3
5
5
3
1
1
1
9
6
14
3
11
5
90
LECTURER/INSTRUCTOR
CE
M. Sönmezoğlu /
G. Çelik
F. Kaleağasıoğlu / E. Genç
I. D. Ekici / F. Özkan
TOTAL
24
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
1
0
4
3
2
15
1
0
6
1
1
7
1
1
5
1
1
7
2
0
7
1
1
5
1
1
3
1
1
3
1
0
2
2
1
12
2
1
9
2
0
16
1
1
5
3
1
15
1
1
7
25/200
13/100
128
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
2
-
-
2
2
1
5
-
-
2
1
5
PHASE III
COMMITTEE I
INFECTIOUS DISEASES
I. WEEK
DAY
HOUR
SUBJECT
08-Sep-2014
14:00-14:50
Introduction to Phase III
MONDAY
15:00-15:50
16:00-16:50
17.00-17.50
Semiology-I
Semiology-II
Independent study hours
09-Sep-2014
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Diagnosis of Infectious Diseases I
Diagnosis of Infectious Diseases II
Introduction to Antimicrobial Chemotherapy
Introduction to the Course I
G. Çelik
G. Çelik
F. Kaleağasıoğlu
E. Vatanoğlu
Introduction to the Course II
Independent study hours
Independent study hours
Independent study hours
E. Vatanoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
ß Lactam Antibiotics I
ß Lactam Antibiotics II
Physician-Patient Relationship I
Physician-Patient Relationship II
F. Kaleağasıoğlu
F. Kaleağasıoğlu
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
Public Health and Communicable DiseasesI
Public Health and Communicable DiseasesII
Epidemiology of Communicable Diseases I
Epidemiology of Communicable Diseases II
R.E. Sezer
Vancomycin & Other Antimicrobial Drugs
Macrolids
Scientific Project - III: Project Writing
Independent study hours
F. Kaleağasıoğlu
F. Kaleağasıoğlu
G. Y. Demirel
Tissue Response to Infections
Pathology of Mycobacterial Infections
Tuberculosis & Other Mycobacterial
Infections I
Tuberculosis & Other Mycobacterial
Infections II
I. D. Ekici
I. D. Ekici
İ.Ç. Acuner
10-Sep-2014
WEDNESDAY
11-Sep-2014
THURSDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
12-Sep-2014
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
LECTURER
Phase III
Coordination
Committee
Y. Küçükardalı
Y. Küçükardalı
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
25
R.E. Sezer
H.A.Taşyıkan
H.A.Taşyıkan
M. Sönmezoğlu
II. WEEK
DAY
15-Sep-2014
MONDAY
HOUR
SUBJECT
09.00-09.50
10.00-10.50
11.00-11.50
Pathophysiology of Infectious Diseases I
Pathophysiology of Infectious Diseases II
Principles of Autonomy and Informed
Consent I
Principles of Autonomy and Informed
Consent II
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
16-Sep-2014
TUESDAY
18-Sep-2014
THURSDAY
19-Sep-2014
FRIDAY
Prevention and Control of Communicable
Diseases I
Prevention and Control of Communicable
Diseases II
Investigation of a Disease Outbreak or
Epidemic I
Investigation of a Disease Outbreak or
Epidemic II
E. Vatanoğlu
E. Vatanoğlu
R.E. Sezer
R.E. Sezer
H.A.Taşyıkan
H.A.Taşyıkan
Pathology of the Parasitic Infections
Parasitic Infections I
Fungal and parasitic skin and soft tissue
infections
Pathology of Fungal Infections
F. Özkan
Y. Gürol
Introduction of Clinical Genetics
Inherited Immun System Disorders
Confidentiality and Truthfulness I
Confidentiality and Truthfulness II
A. Ç. Kuşkucu
A. Ç. Kuşkucu
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Pathology of Mycobacterial Infections
Pathology of Bacterial Infections
Antimycobacterial Drugs
Quinolones
F. Özkan
F. Özkan
E. Genç
F. Kaleağasıoğlu
09.00-09.50
Bacterial and Viral Skin & Soft Tissue
Infections
Zoonotic Diseases I
Zoonotic Diseases II
Parasitic infections II
M. Sönmezoğlu
Antifungal Drugs
Antiprotozoal Drugs
Research Design
Research Design
F. Kaleağasıoğlu
F. Kaleağasıoğlu
Ç. Kaspar
Ç. Kaspar
Antimalarial Drugs
Antiviral Drugs
Hospital Infection
Febril Neutropenia
F. Kaleağasıoğlu
F. Kaleağasıoğlu
M. Sönmezoğlu
M. Sönmezoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
17-Sep-2014
WEDNESDAY
LECTURER
M. Kaçar
M. Kaçar
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
Y. Gürol
F. Özkan
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
26
M. Sönmezoğlu
M. Sönmezoğlu
M. Sönmezoğlu
III. WEEK
DAY
HOUR
SUBJECT
LECTURER
22-Sep-2014
09.00-09.50
E. Genç
MONDAY
10.00-10.50
Aminoglycosides
Sulfonamides, Chloramphenicol &
Tetracyclines
Pathology of Viral Infections I
Pathology of Viral Infections II
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
23-Sep-2014
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
24-Sep-2014
WEDNESDAY
25-Sep-2014
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Planning Medical Studies
Planning Medical Studies
Emergency Evaluation of Sepsis and
Septic Shock
Approach to the Pediatric Patient with
Fever
Ç. Kaspar
Ç. Kaspar
Antihelmintic Drugs
Antiseptics and Disinfectants
Occupational Health Hazards I
Occupational Health Hazards II
F. Kaleağasıoğlu
F. Kaleağasıoğlu
G. Çelik
G. Çelik
CSL Group II
(Intravenous Injection & IV Cannulation)
S. Sarıkaya
09.00-11.50
CSL Group III
(Intravenous Injection& IV Cannulation)
09.00-11.50
12.00-12.50
13.00-17.50
S. Sarıkaya
G. Çelik
G. Çelik
Independent study hours
12.00-12.50
13.00-17.50
I. D. Ekici
I. D. Ekici
Infections in Immuncompromised Host
Vaccines
Introduction to the Program of Family
Medicine
Approach to the Patient with Fever in
Primary Care
17.00-17.50
THURSDAY
26-Sep-2014
FRIDAY
CSL Group I
(Intravenous Injection & IV Cannulation)
Independent study hours
E. Genç
G. İzbırak
Ö. Tanrıöver
S. Sarıkaya
Ş. Özdoğan
S. Sarıkaya
Independent study hours
CSL Group IV
(Intravenous Injection& IV Cannulation)
Independent study hours
27
S. Sarıkaya
IV. WEEK
DAY
HOUR
SUBJECT
LECTURER
29-Sep-2014
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
Microbiology Laboratory Techniques
and Diagnostic Tests Group I
Microbiology Laboratory Techniques
and Diagnostic Tests Group II
İ.Ç.Acuner/ Y.G
urol/G.Çelik
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
30-Sep-2014
TUESDAY
01-Oct-2014
WEDNESDAY
02-Oct-2014
THURSDAY
03-07-Oct
2014
FRIDAYTUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Microbiology Laboratory Techniques
and Diagnostic Tests Group III
Microbiology Laboratory Techniques
and Diagnostic Tests Group IV
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
10.00-13.00
COMMITTEE EXAM
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Religious Holiday
28
İ.Ç.Acuner/
Y.Gurol/G.Çelik
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II
DISTRIBUTION of LECTURE HOURS
October 8, 2014 – November 28 , 2014
COMMITTEE DURATION: 8 WEEKS
DISCIPLINE

PHARMACOLOGY

PATHOLOGY

ABBR.
THEO.
PC
25
PRAC.
LAB/CSL
DISCUSSION TOTAL
25
1x3=3
(2 Groups)
27
PT
24
CHEST MEDICINE
CHM
17

CARDIOLOGY
CRD
14
14


PH
9
9
BED
9
9
PP
6
6
IDCM
5
5

PUBLIC HEALTH
BIOMEDICAL ETHICS &
DEONTOLOGY
PATHOPHYSIOLOGY
INFECTIOUS DISEASES &
CLINICAL MICROBIOLOGY
ENT DISEASES
ENT
4
4

THORACIC SURGERY
TS
3
3

FAMILY MEDICINE
FM
3
3

MEDICAL GENETICS
MG
2
2

BIOISTATISTICS
BS
2

PEDIATRICS
PED
2
2

RADIOLOGY
RAD
1
1

EMERGENCY MEDICINE
EM
1
1

SCIENTIFIC PROJECTS-III
SP
1



CLINICAL SKILLS LAB
TOTAL
1x1=1
1x2=2
3
2x3=6
(4 Groups)
6
6
3
Coordination Committee
HEAD
Sevda Özdoğan, MD, Prof.
SECRETARY
Olcay Özveren, MD, Assist. Prof
MEMBER
Ferda Kaleağasıoğlu, MD Assoc. Prof.
MEMBER
Ferda Özkan, MD Prof.
Özlem Tanrıöver, MD, Assoc Prof
(Co-coordinator)
MEMBER
29
4
1
CSL
128
18
140
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II
LECTURERS
DISCIPLINE
CARDIOLOGY
CHEST MEDICINE
THORACIC SURGERY
PATHOLOGY
PATHOPHYSIOLOGY
PHARMACOLOGY
PUBLIC HEALTH
FAMILY MEDICINE
PEDIATRICS
CLINICAL SKILLS LAB
RADIOLOGY
EAR- NOSE -THROAT (ENT)
INFECTIOUS DISEASES &
LECTURERS
Muzaffer Değertekin, MD Prof.
Zekeriya Küçükdurmaz, MD Assoc. Prof.
Olcay Özveren, MD Assist. Prof.
Emine Sevda Özdoğan, MD Prof.
Sina Ercan, MD Prof.
Ferda Özkan, MD Prof.
Işın Doğan Ekici, MD Assoc. Prof.
Mehtap Kaçar, MD PhD Assist. Prof.
Ece Genç, PhD Prof.
Ferda Kaleağasıoğlu MD, Assoc. Prof.
Recep Erol Sezer, MD, Prof.
Hale Arık Taşyıkan, MD, Assist. Prof.
Güldal İzbırak, MD Assoc.Prof.
Özlem Tanrıöver, MD Assoc.Prof.
Defne Çöl, MD Assist. Prof.
Zekeriya Küçükdurmaz, MD Assoc. Prof
Olcay Özveren, MD Assist. Prof.
Ferdi Menda MD Assoc.Prof.
Neslihan Taşdelen, MD Assoc.Prof.
Ali Özgen, MD
Yavuz Selim Pata, MD Prof.
Müzeyyen Doğan, MD Assoc. Prof.
CLINICAL MICROBIOLOGY
Gülden Çelik, MD Prof.
Meral Sönmezoğlu, MD Assoc. Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
BIOMEDICAL ETHICS &
DEONTOLOGY
Elif Vatanoğlu, MD, Assist. Prof
EMERGENCY MEDICINE
Sezgin Sarıkaya, MD Assoc.Prof.
BIOSTATISTICS
Çiğdem Kaspar, PhD, Assist. Prof
SCIENTIFIC PROJECTS- III
Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.
30
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE II
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of cardiovascular and respiratory
systems,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency related to cardiovascular and respiratory systems,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to cardiovascular and respiratory systems,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or
improvement of health against those clinical conditions related to cardiovascular and respiratory
systems,
5. to convey knowledge on mechanisms of occurrence for frequently encountered clinical
complaints, symptoms, signs and findings in clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to cardiovascular and respiratory systems,
6. to convey necessary knowledge together with performance measures on health care
processes, clinical decision making process, clinical decisions and clinical practices required for
managing clinical conditions related to cardiovascular and respiratory systems, which are
frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency, at the level of primary health care service,
7. to convey knowledge on principles of prescription,
8. to convey necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. to convey necessary knowledge on radiation physics and biology and its use in oncology,
10. to convey necessary knowledge on ethical problems encountered in health care service and
utilization, and on principles of solutions,
11. to convey knowledge on principles of biostatistical analysis,
12. to convey knowledge on use of phytotherapy in an evidence based manner and drug
interactions in phytotherapy,
13. to equip with basic and advanced clinical skills (advanced cardiac life support-C2,
approach to patient with cardiovascular clinical condition-C2) required at primary health care
service level.
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.recall anatomy, histology and physiology of cardiovascular and respiratory systems,
31
2.explain etiopathogenesis of clinical conditions (upper respiratory tract problems -nasal obstruction,
etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism,
etc.-,
obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use, lung tumors,other lung
diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves,
myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults
and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and
paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice
disorders) which are frequent in community and/or pose high risk for individual or community health,
and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3.explain epidemiology of clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to
cardiovascular and respiratory systems,
4.explain prevention of clinical conditions, and protection or improvement of health against those clinical
conditions related to cardiovascular and respiratory systems,
5.describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs
and findings in clinical conditions which are frequent in community and/or pose high risk for individual
or community health, and/or life-threatening or constitute an emergency related to cardiovascular
and respiratory systems,
6.at multi-system level and/or related to cardiovascular and respiratory systems,
 for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
 in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
 for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes, health care processes, clinical decision making process, clinical
decisions and clinical practices
 which are required for management at primary health care service level:
6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)
6.2. evaluation of emergency case (dyspnea-C2)
6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and
hemoptysis-C2, dyspnea-C2)
6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary
function tests-C2)
6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac
PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2)
6.6. point of care testing (urine strip/dipstick test-C1)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7.define radiation physics, biology and its use in oncology,
8.explain principles of prescription,
9.explain pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology,
renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to
ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, antihypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and
thrombolytic drugs, bronchodilator drugs, antitussive, expectorant and surfactant drugs),
10.explain ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive
and negative rights),
11.explain principles of biostatistical analysis,
12.explain use of phytotherapy in an evidence based manner, and drug interactions in phytotherapy,
13. perform basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and
advanced clinical skills, practiced on simulated/standardized patients (approach to patient with
cardiovascular clinical condition-C2), required at primary health care service.
32
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE II
CARDIOVASCULAR & RESPIRATORY SYSTEMS
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0.,2.0.
1.0.,2.0.
1.0.,2.0.,5.0.,6.0.
1.0.,2.0.,5.0.,6.0.
1.0.,2.0.,5.0.,6.0.
1.0.,2.0.,5.0.,6.0.
1.0.,2.0.,5.0.,6.0.6.4.
1.0.,2.0., 5.0., 6.0.6.1.,6.3.
1.0.,2.0.,5.0.,6.0.6.4.
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.
2.0.,5.0.
2.0.,5.0.
2.0.,5.0.,6.0.
2.0.,5.0.,6.4.
3.0.,4.0.
3.0.,4.0.
6.2.
6.3.
6.3.
6.5.
8.0.,9.0.
9.0.
10.0.
11.0.
FACULTY
DEPARTMENT
LECTURER/INSTRUCTOR
F. Özkan
I D. Ekici
M. Doğan
Y. S. Pata
D. Çöl
S. Ercan
M. Değertekin
Z. Küçükdurmaz
O. Özveren
S. Özdogan
A.Ç. Kuskucu
M. Kaçar
M. Sönmezoğlu
G. Çelik
R.E. Sezer
H.A.Taşyıkan
S. Sarıkaya
G. İzbırak
Ö. Tanrıöver
N. Tasdelen / A. Özgen
F. Kaleağasıoğlu
E. Genç
E. Vatanoğlu
Ç. Kaspar
PT
PT
ENT
ENT
PED
TS
CRD
CRD
CRD
CHM
MG
PP
IDCM
IDCM
PH
PH
EM
FM
FM
RAD
PC
PC
BED
BS
TOTAL
LEARNING OBJECTIVE
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6
.
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.
8.0.,9.0.
FACULTY
DEPARTMENT
CE
9
10
1
1
1
2
1
3
4
12
1
4
2
1
4
3
1
1
1
1
13
5
7
3
91
LECTURER/INSTRUCTOR
CE
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
2
1
12
3
2
15
0
0
1
0
0
1
0
1
2
1
1
4
0
0
1
1
1
5
1
1
6
4
1
17
0
0
1
1
1
6
1
0
3
0
0
1
1
0
5
1
1
5
0
0
1
0
0
1
0
0
1
0
0
1
4
1
18
1
1
7
2
1
10
1
1
5
24/200
14/100
129
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
CHM
S. Özdogan
2
-
-
2
CRD
PC
O. Özveren
E. Genç
2
1
5
-
-
2
1
5
TOTAL
33
PHASE III
COMMITTEE II
CARDIOVASCULAR and RESPIRATORY SYSTEM
I.WEEK
03-07 Oct2014
RELIGIOUS HOLIDAY
08-10 Oct
2014
Independent study hours
II. WEEK
DAY
HOUR
13-Oct-2014
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
14-Oct-2014
09.00-09.50
TUESDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
15-Oct-2014
WEDNESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
SUBJECT
LECTURER
Introduction to Committee II
Pathophysiology of Cardiovascular System
Disorders I
Pathophysiology of Cardiovascular System
Disorders II
Pathophysiology of Cardiovascular System
Disorders III
Independent study hours
Epidemiology and Prevention of Cardiovascular
Diseases I
Epidemiology and Prevention of Cardiovascular
Diseases II
Epidemiology and Prevention of Cardiovascular
Diseases III
Discussion hour for the Committee I exam
questions
Examination of the Heart
Approach to the patient with Cardiovascular
System Diseases
General Signs and Principal Symptoms in
Cardiovascular System Diseases
Introduction to Autonomic System Pharmacology
M. Kaçar
M. Kaçar
M. Kaçar
H.A.Taşyıkan
H.A.Taşyıkan
H.A.Taşyıkan
G. Çelik and
Committee I
Coordination
Committee
Members
M. Değertekin
Z. Küçükdurmaz
O. Özveren
E. Genç
Principles of Beneficence and Nonmaleficence I
Principles of Beneficence and Nonmaleficence II
Independent study hours
Independent study hours
E. Vatanoğlu
E. Vatanoğlu
Electrocardiography I
Electrocardiography II
Preparing to analyse data
Preparing to analyse data
Z. Küçükdurmaz
Z. Küçükdurmaz
Ç. Kaspar
Ç. Kaspar
Acetylcholine and Directly Acting
Parasympathomimetic Drugs
Acetylcholinesterase Inhibitors
Independent study hours
Independent study hours
E. Genç
34
E. Genç
16-Oct-2014
THURSDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
17-Oct-2014
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
Coronary Artery Disease I
Coronary Artery Disease II
Cardiac Arrhytmias I
Cardiac Arrhytmias II
M. Değertekin
M. Değertekin
Z. Küçükdurmaz
Z. Küçükdurmaz
Approach to the Patient with Dyspnea in Primary
Care
End of Life decisions I
Independent study hours
Independent study hours
Ö. Tanrıöver
Congestive Heart Failure
Congestive Heart Failure & Pericardium
Myocardium
F. Özkan
F. Özkan
F. Özkan
Congestive Heart Failure I
Congestive Heart Failure II
Approach to the Pediatric Patient with Pneumonia
Independent study hours
Independent study hours
O. Özveren
O. Özveren
Ş. Özdoğan
35
E. Vatanoğlu
III. WEEK
DAY
20-Oct-2014
MONDAY
21-Oct-2014
TUESDAY
22-Oct-2014
WEDNESDAY
23-Oct-2014
THURSDAY
HOUR
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
SUBJECT
Diuretic Agents I
Diuretic Agents II
End of Life Decisions II
End of Life Decisions III
LECTURER
F. Kaleağasıoğlu
F. Kaleağasıoğlu
E. Vatanoğlu
E. Vatanoğlu
Ischemic Heart Disease I
Ischemic Heart Disease II
Independent study hours
Independent study hours
F. Özkan
F. Özkan
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
Pathology of Endocardium & Heart Valves I
Pathology of Endocardium & Heart Valves II
Pharmacology of Renin-Angiotensin System
I D. Ekici
I D. Ekici
F. Kaleağasıoğlu
Ethics of Distribution I
Ethics of Distribution II
Bloodstream Invasion & Sepsis I
Bloodstream Invasion & Sepsis II
Independent study hours
E. Vatanoğlu
E. Vatanoğlu
G. Çelik
M. Sönmezoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
Aortic Valvular Heart Diseases
Infective Endocarditis and Acute Rheumatic fever
Anti-hypertensive Drugs-I
Anti-hypertensive Drugs-II
O. Özveren
O. Özveren
F. Kaleağasıoğlu
F. Kaleağasıoğlu
09.00-09.50
10.00-10.50
11.00-11.50
Cardiac Infections
Atherosclerosis & Hypertension I
Atherosclerosis & Hypertension II
Approach to Patient with Chest Pain in Primary
Care
12.00-12.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
M. Sönmezoğlu
I.D. Ekici
I.D. Ekici
G. İzbırak
13.00-13.50
14.00-16.50
17:00-17:50
24-Oct-2014
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
CSL Group III (Advanced Cardiac Life
Support)
Independent study hours
F. Menda
Mitral Valvular Heart Diseases
Rheumatic Heart Disease
CVS Tumors
Drugs Used in Congestive Heart Disease I
O. Özveren
I D. Ekici
I D. Ekici
F. Kaleağasıoğlu
Drugs Used in Congestive Heart Disease II
Independent study hours
Independent study hours
Independent study hours
F. Kaleağasıoğlu
36
IV. WEEK
DAY
27-Oct-2014
MONDAY
HOUR
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
28-29 Oct2014
SUBJECT
Congenital Heart Disease in Pediatrics
Congenital Heart Disease I
Congenital Heart Disease II
LECTURER
D. Çöl
I. D. Ekici
Parasympatholitic Drugs
Sympathomimetic Drugs: Catecholamines &
Noncatecholamines
Independent study hours
Independent study hours
E. Genç
I. D. Ekici
E. Genç
National Holiday
30-Oct-2014
09.00-09.50
THURSDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
31-Oct-2014
09.00-09.50
FRIDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
History and Symptoms in Pulmonary Diseases
S. Özdoğan
Physical Examination and Signs in Pulmonary
Diseases
Adrenergic Receptor Blockers
Adrenergic Neuron Blockers
S. Özdoğan
Tobacco Control and Chronic Non-Communicable
Diseases I
Tobacco Control and Chronic Non-Communicable
Diseases II
Independent study hours
Independent study hours
E. Genç
E. Genç
R.E. Sezer
R.E. Sezer
Drugs Used in Cardiac Arrythmias I
Drugs Used in Cardiac Arrythmias II
F. Kaleağasıoğlu
F. Kaleağasıoğlu
Drugs Used in the Treatment of Angina Pectoris
Inherited Cardiovascular Disorders
F. Kaleağasıoğlu
A.Ç. Kuşkucu
Tobacco Control and Chronic Non-Communicable
Diseases III
Tobacco Control and Chronic Non-Communicable
Diseases IV
Independent study hours
Independent study hours
37
R.E. Sezer
R.E. Sezer
V. WEEK
DAY
03-Nov-2014
MONDAY
HOUR
SUBJECT
LECTURER
09.00-09.50
Pathophysiology of Respiratory System Disorders
I
Pathophysiology of Respiratory System Disorders
I
Pathophysiology of Respiratory System Disorders
I
Anticoagulant, Antiplatelet & Thrombolytic Drugs
M. Kaçar
CSL Group I (Advanced Cardiac Life Support)
Independent study hours
F. Menda
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16 50
Drugs Used in the Treatment of Dyslipidemias I
Drugs Used in the Treatment of Dyslipidemias II
Diagnostic Methods in Pulmonary Medicine
Clinical Application of Pulmonary Function Tests
F. Kaleağasıoğlu
F. Kaleağasıoğlu
S. Özdoğan
S. Özdoğan
CSL Group IV (Advanced Cardiac Life Support)
F. Menda
17.00-17.50
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-17.50
Pulmonary Tuberculosis
Pleural Diseases
Pathology of Upper Respiratory Tract
S. Özdoğan
S. Özdoğan
F. Özkan
Pulmonary Infections I
Pulmonary Infections II
Independent study hours
F. Özkan
F. Özkan
09.00-09.50
10.00-10.50
11.00-11.50
Lung Diseases and Tobacco
Interstitial Lung Diseases
12.00-12.50
13.00-13.50
14.00-16.50
Scientific Projects- III: Project Writing
S. Özdoğan
S. Özdoğan
N.Tasdelen/
A. Özgen
G. Y. Demirel
CSL Group II (Advanced Cardiac Life Support)
F. Menda
17.00-17.50
Independent study hours
09.00-09.50
10.00-10.50
Bronchial Hyperreactivity and Asthma
Chronic Obstructive Pulmonary Disease
Respiratory Muscles and Surgical Anatomy of
Thorax
Surgical Disorders of Mediastinum and the
Diaphragm
S. Özdoğan
S. Özdoğan
Surgical Treatment of Pulmonary Diseases
Pharmacology and Toxicology of Tobacco
Drugs Used in the Treatment of Asthma &
Chronic Obstructive Lung Disease
Independent study hours
S. Ercan
F. Kaleağasıoğlu
F. Kaleağasıoğlu
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
04-Nov-2014
TUESDAY
05-Nov-2014
WEDNESDAY
06-Nov-2014
THURSDAY
07-Nov-2014
FRIDAY
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
X-Ray Examination of the Lungs
38
M. Kaçar
M. Kaçar
F. Kaleağasıoğlu
S. Ercan
S. Ercan
VI. WEEK
DAY
10-Nov-2014
MONDAY
11-Nov-2014
TUESDAY
SUBJECT
09.00-09.50
10.00-10.50
11.00-11.50
12.00-17.50
LECTURER
Commomeration of Ataturk: Rectorate
Building, Inan Kıraç Conference Hall
Independent study hours
Sleep Apnea Syndrome
Lung Cancer
Tracheobronchitis
Treatment of Cough &Drugs Used in the
Treatment of Common Cold
S. Özdoğan
S. Özdoğan
S. Özdoğan
F. Kaleağasıoğlu
14.00-16.50
CSL GROUP IV
(Approach to the patient with cadiovascular
disorders)
Z. Küçükdurmaz /
O. Özveren
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Pneumonia
Respiratory Failure
Principals of Statistical Analysis
Principals of Statistical Analysis
S. Özdoğan
S. Özdoğan
Ç. Kaspar
Ç. Kaspar
14.00-16.50
CSL GROUP I
(Approach to the patient with cardiovascular
disorders)
Independent study hours
Z. Küçükdurmaz /
O. Özveren
Chronic Obstructive Pulmonary Diseases
Asthma Bronchiale
Congenital Lung Anomalies & Atalectasis
Emergency Evaluation of Dyspnea
F. Özkan
F. Özkan
F. Özkan
S. Sarıkaya
Laryngeal and Voice Diseases
Diseases of the Middle Ear and Eustachian Tube
Epidemiology, Prevention and Control of Chronic
Non-Communicable Respiratory Diseases
Public Health and Chronic Non-Communicable
Diseases
M. Doğan
M. Doğan
Tumors of the Respiratory System I
Tumors of the Respiratory System II
Pathology of Pleural and Mediastinal Diseases
Hypertension Treatment Guidelines
I.D. Ekici
I.D. Ekici
I.D.Ekici
F. Kaleağasıoğlu
Approach to the Patient with Cough and
Heameoptysis in Primary Care
Diseases of the Nose and Paranasal Sinuses
Nasopharyngeal and Oropharyngeal Diseases
Independent study hours
Ö. Tanrıöver
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
12-Nov-2014
WEDNESDAY
17.00-17.50
13-Nov-2014
THURSDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
14-Nov-2014
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
39
R.E. Sezer
H.A.Taşyıkan
Y. S. Pata
Y. S. Pata
VII. WEEK
DAY
17-Nov-2014
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
18-Nov-2014
TUESDAY
19-Nov-2014
WEDNESDAY
20-Nov-2014
THURSDAY
SUBJECT
LECTURER
Pulmoner Hypertension
Special Pulmonary Problems
End of Life Decisions I
End of Life Decisions II
S. Özdoğan
S. Özdoğan
E. Vatanoğlu
E. Vatanoğlu
Pathology LAB I
F. Özkan/
I.D. Ekici
F. Özkan/
I.D. Ekici
F. Özkan/
I.D. Ekici
15.00-15.50
Pathology LAB I
16.00-16.50
Pathology LAB I
17.00-17.50
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Pulmonary Embolism
Chest Medicine Case Report
Pharmacology Case Studies
Inherited Respiratory System Disorders
14.00-14.50
Pathology LAB II
15.00-15.50
Pathology LAB II
16.00-16.50
Pathology LAB II
17.00-17.50
Independent study hours
09.00-11.50
CSL Group III
(Approach to the patient with cardiovascular
disorders)
12.00-12.50
13.00-17.50
Independent study hours
09.00-12.50
Independent study hours
S. Özdoğan
S. Özdoğan
F. Kaleağasıoğlu
A.Ç. Kuşkucu
F. Özkan/ I.D.
Ekici
F. Özkan/ I.D.
Ekici
F. Özkan/ I.D.
Ekici
Z.Küçükdurmaz /
O.Özveren
13.00-13.50
14.00-16.50
21-Nov-2014
FRIDAY
17.00-17.50
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
CSL Group II
(Approach to the patient with cardiovascular
disorders)
Independent study hours
Upper and Lower Respiratory System Infections I
Upper and Lower Respiratory System Infections
II
Chronic Restrictive Pulmonary Diseases I
Chronic Restrictive Pulmonary Diseases II
Independent study hours
40
Z. Küçükdurmaz /
O. Özveren
G. Çelik
M. Sönmezoğlu
I D. Ekici
I D. Ekici
VIII. WEEK
DAY
24-Nov- 2014
MONDAY
HOUR
09.00-17.50
SUBJECT
Independent study hours
25-Nov-2014
TUESDAY
09.00-17.50
Independent study hours
26-Nov-2014
WEDNESDAY
09.00-17.50
Independent study hours
27-Nov-2014
THURSDAY
09.00-17.50
Independent study hours
28-Nov-2014
FRIDAY
10.0013.00
COMMITTEE EXAM
41
LECTURER
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
COMMITTEE III
HEMATOPOIETIC SYSTEM
DISTRIBUTION of LECTURE HOURS
December, 01 2014 – December, 19 2014
COMMITTEE DURATION: 3 WEEKS

DISCIPLINE

HAEMATOLOGY

ABBR.
THEO.
HEM
17
17
PATHOLOGY
PT
10
10

PHARMACOLOGY
PC
9
9


PED
7
7
IDCM
4
4

PEDIATRICS
INFECTIOUS DISEASES &
CLINICAL MICROBIOLOGY
MEDICAL GENETICS
MG
3
3

PHYTOTHERAPY
PHY
3
3

ONCOLOGY
ONC
3
3

PATHOPHYSIOLOGY
PP
2
2


BS
2
BED
2
2

BIOISTATISTICS
BIOMEDICAL
ETHICS&DEONTOLOGY
FAMILY MEDICINE
FM
1
1

SCIENTIFIC PROJECTS- III
SP
1
1

CLINICAL SKILLS LAB
TOTAL
CSL
64
PRAC.
LAB/CSL
DISCUSSION TOTAL
1X2=2
1X3=3
(4 Groups)
3
3
2
Coordination Committee
HEAD
Işın D. Ekici , MD Assoc. Prof
SECRETARY
Orhan Ender Eren , MD Assist. Prof
Atilla Özkan, MD Assist. Prof
Mehtap Kaçar, MD PhD Assist. Prof.
(Co-coordinator)
MEMBER
MEMBER
42
4
69
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
HEMATOPOIETIC SYSTEM
COMMITTEE III
LECTURERS
DISCIPLINE
HAEMATOLOGY
Atilla Özkan MD Assist.Prof.
ONCOLOGY
Orhan Önder Eren, MD Assist Prof.
PATHOLOGY
Ferda Özkan, MD Prof.
A.Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY
CLINICAL SKILLS LAB
Mehtap Kaçar, MD PhD Assist. Prof.
Ece Genç, PhD Prof.
Ferda Kaleağasıoğlu, MD, Assoc. Prof.
Erdem YEŞİLADA, PhD, Prof.
Ayça Vitrinel, MD Prof.
Mehmet Reha Cengizlier, MD Prof.
Filiz Bakar, MD Prof.
Sevgi Bilgen, MD Assist Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL
MICROBIOLOGY
Gülden Çelik, MD Prof.
Meral Sönmezoğlu, MD Assoc. Prof.
BIOSTATISTICS
Çiğdem KASPAR, PhD Assist. Prof.
PHARMACOLOGY
PHYTOTHERAPY
PEDIATRICS
LECTURERS
BIOMEDICAL ETHICS&DEONTOLOGY Elif Vatanoğlu, MD PhD Assist. Prof.
FAMILY MEDICINE
Hülya Akan, MD Assoc. Prof.
SCIENTIFIC PROJECTS - III
Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.
43
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
HEMATOPOIETIC SYSTEM
COMMITTEE III
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of hematopoietic system,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to cardiovascular and respiratory systems,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency
related to hematopoietic system,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or improvement
of health against those clinical conditions related to hematopoietic system,
5. to convey knowledge on mechanisms of occurrence for frequently encountered clinical complaints,
symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high
risk for individual or community health, and/or life-threatening or constitute an emergency related to
hematopoietic system,
6. to convey necessary knowledge together with performance measures on health care processes,
clinical decision making process, clinical decisions and clinical practices required for managing
clinical conditions related to hematopoietic system, which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency, at
the level of primary health care service,
7. to convey knowledge on pharmacology of drugs that are effective on hematopoietic system or on
clinical conditions involving hematopoietic system,
8. to convey knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. to convey knowledge on comparative biostatistical analysis of study groups,
10. to equip with basic and advanced clinical skills (arterial blood sample collection-C3) required at
primary health care service level.
44
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1. recall anatomy, histology and physiology of hematopoietic system,
2. explain etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases,
lenforeticular infections) which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency related to hematopoietic
system,
3. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
hematopoietic system,
4. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to hematopoietic system,
5. describe mechanims of occurence for frequently encountered clinical complaints, symptoms, signs
and findings in clinical conditions which are frequent in community and/or pose high risk for individual
or community health, and/or life-threatening or constitute an emergency related to hematopoietic
system,
6. at multi-system level and/or related to hematopoietic system,
• for healthy conditions in an individual or community with a request against clinical conditions that
pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
6.1. practice of history taking and physical examination
6.2. evaluation of emergency case
6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3,
hematology tests for anemia-C3)
6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete
blood count-)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7. classify blood products and blood groups,
8. define principles of transfusion,
9. explain pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and
blood products, immunomodulators) that are effective on hematopoietic system or on clinical
conditions involving hematopoietic system,
10. explain mechanisms of bone marrow toxicity of drugs and other chemicals,
11. list principles of cancer chemotherapy,
12. explain chemotherapy in leukemia and lymphoma,
13. list phytotherapeutic agents with immunomodulatory effects,
14. list principles of comparative biostatistical analysis of study groups,
15. perform basic clinical skills, practiced on phantom models (arterial blood sample collection-C3),
required at primary health care service.
45
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE III
HEMATOPOIETIC SYSTEM
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
2.0.
2.0.,5.0.
2.0.,5.0.,6.4.
2.0.-6.0.
2.0.-6.4.
6.3.
9.0.-12.0.
9.0.-12.0.
14.0.
10.0
FACULTY
DEPARTMENT
HEM
IM-ONC
PED
PED
PED
MG
PP
PT
IDCM
IDCM
FM
PC
PC
BS
BED
PHR
LECTURER / INSTRUCTOR
A. Özkan
O Ö.Eren
A. Vitrinel
M.R. Cengizlier
F. Bakar
A. Ç. Kuşkucu
M. Kaçar
I D. Ekici
M. Sönmezoğlu
G. Çelik
H. Akan
E. Genç
F. Kaleağasıoğlu
Ç. Kaspar
E. Vatanoğlu
E. Yeşilada
TOTAL
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
2.0.,5.0.,6.4.
FACULTY
DEPARTMENT
HEM
PED
PT
CE
22
4
4
4
4
4
2
14
5
2
1
2
8
7
4
3
90
LECTURER / INSTRUCTOR
A. Özkan
O Ö. Eren
F. Kaleağasıoğlu
TOTAL
46
CE
2
2
1
5
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
7
3
32
1
1
6
1
1
6
1
0
5
1
0
5
1
1
6
1
0
3
4
2
20
1
1
7
1
0
3
1
0
2
0
0
2
2
1
11
1
1
9
1
1
6
1
1
5
25/200
13/100
128
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
2
2
1
5
-
PHASE III
COMMITTEE III
I. WEEK
DAY
HOUR
01-Dec-2014
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-17.50
02-Dec-2014
09.00-09.50
TUESDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
HEMATOPOIETIC SYSTEM
SUBJECT
Introduction to Committee III
Introduction to Hematology, Signs and
Symptoms in Hematological Diseases
Classification of Anemias
Pathophysiology of Hematopoietic System
Disorders I
Pathophysiology of Hematopoietic System
Disorders II
LECTURER
Pathology of Bone Marrow-1
Pathology of Bone Marrow-2
I D. Ekici
I D. Ekici
S. Özdoğan and
Committee II
Coordination
Committee members
Discussion hour for the Committee II
exam questions
M. Kaçar
A. Özkan
A. Özkan
M. Kaçar
M. Kaçar
Immune Acquired Hemolytic Anemias / Non
Immune Acquired Hemolytic Anemias
Thalassemias and Hemoglobinopathies
(Sickle Cell Anemia and Others)
Disorders of White Blood Cells& Leukemia I
Disorders of White Blood Cells& Leukemia II
A.Özkan
CSL Group I
(Femoral / Radial Arterial Puncture)
S. Bilgen
A.Özkan
I D. Ekici
I D. Ekici
17.00-17.50
Independent study hours
03-Dec-2014
09.00-09.50
A.Özkan
WEDNESDAY
10.00-10.50
Iron Metabolism and Iron Deficiency Anemia
Vitamin B12 and Folic acid Metabolism and
Megaloblastic Anemias
Hodgkin’s Lymphoma
Antianemic Drugs
Molecular Basis of Hemoglobinopathies
Introduction to Clinical Oncology-I
Introduction to Clinical Oncology-II
Treatment Approaches of Cancer
A. Ç. Kuşkucu
O Ö.Eren
O Ö.Eren
O Ö.Eren
Approach to the Patient with Anemia and
Laboratory Tests in Diagnosis with Anemia
Hematopoiesis: Stem Cell and Bone Marrow
Aplastic and Hypoplastic Anemias
Pharmacological Basis of Cancer Therapy I
CSL Group II
(Femoral / Radial Arterial Puncture)
Independent study hours
A.Özkan
Chronic Leukemia
Lymphoma
Introduction to Anemias in Childhood
Introduction to Hemolytic Anemias
A. Özkan
A.Özkan
A. Vitrinel
A. Vitrinel
Scientific Projects- III: Project Writing
Phytotherapy-I
Phytotherapy-II
Phytotherapy-III
G. Yanıkkaya Demirel
E. Yeşilada
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
04-Dec-2014
THURSDAY
05-Dec-2014
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
14.00-16.50
17.00-17.50
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
47
A.Özkan
I D. Ekici
E. Genç
A.Özkan
A.Özkan
F. Kaleağasıoğlu
S.Bilgen
II. WEEK
DAY
HOUR
SUBJECT
LECTURER
08-Dec-2014
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Acute Leukemias
Myeloproliferative Diseases
Congenital Hemolytic Anemias I
Congenital Hemolytic Anemias II
A.Özkan
A.Özkan
M.R. Cengizlier
M.R. Cengizlier
CSL Group III
(Femoral / Radial Arterial Puncture)
Independent study hours
S.Bilgen
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16:00-17:50
Lenforeticular Infections I
Lenforeticular Infections II
Lymphoreactive Disease
Pathology of Spleen
G. Çelik
M. Sönmezoğlu
I D. Ekici
I D. Ekici
Genetics of Oncology I
Genetics of Oncology II
Independent study hours
A.Ç. Kuşkucu
A.Ç. Kuşkucu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16:00-16:50
17:00-17:50
Pharmacological Basis of Cancer Therapy II
Antineoplastic Drugs I
Non/Hodgkin’s Lymphoma I
Non/Hodgkin’s Lymphoma II
F. Kaleağasıoğlu
F. Kaleağasıoğlu
I. D. Ekici
I. D. Ekici
Responsible Biomedical Research I
Responsible Biomedical Research II
Independent study hours
Independent study hours
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Comparing Groups-categorical Data
Comparing Groups-categorical Data
Antineoplastic Drugs II
Non/Hodgkin’s Lymphoma III
Ç. Kaspar
Ç. Kaspar
F. Kaleağasıoğlu
I. D. Ekici
CSL Group IV
(Femoral / Radial Arterial Puncture)
Independent study hours
S. Bilgen
17:00-17:50
09-Dec-2014
TUESDAY
10-Dec-2014
WEDNESDAY
11-Dec-2014
THURSDAY
14.00-16.50
17:00-17:50
12-Dec-2014
09.00-09.50
FRIDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Hemophilia and other Coagulopathies in
Childhood I
Hemophilia and other Coagulopathies in
Childhood II
Coagulation Defects
Quantitative and Qualitative Platelet
Disorders
Comparing Groups-Continous Data
Comparing Groups-Continous Data
Antineoplastic Drugs III
Immunomodulators
48
F. Bakar
F. Bakar
A. Özkan
A. Özkan
Ç. Kaspar
Ç. Kaspar
F. Kaleağasıoğlu
F. Kaleağasıoğlu
III. WEEK
DAY
HOUR
SUBJECT
LECTURER
15-Dec-2014
09.00-09.50
Blood Components and Transfusion
Indications
Blood Groups
Hypercoagulability
Multiple Myelom
M. Sönmezoğlu
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
E. Genç
16.00-16.50
17.00-17.50
Hematostatic Drugs and Hematostatic Blood
Products I
Hematostatic Drugs and Hematostatic Blood
Products II
Congenital Immunodeficiency Disease
Approach to the Patient with LAP
09.00-17.50
Independent study hours
14.00-14.50
15.00-15.50
16- Dec-2014
TUESDAY
17-Dec-2014
WEDNESDAY
18-Dec-2014
THURSDAY
19-Dec-2014
FRIDAY
09.00-17.50
09.00-17.50
10.00-13.00
Independent study hours
Independent study hours
COMMITTEE EXAM
49
M. Sönmezoğlu
A. Özkan
A. Özkan
E. Genç
M.R. Cengizlier
H. Akan
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
COMMITTEE IV
GASTROINTESTINAL SYSTEM
DISTRIBUTION of LECTURE HOURS
December 22, 2014 - January 15, 2015
COMMITTEE DURATION: 4 WEEKS

DISCIPLINE

ABBR.
THEO.
PATHOLOGY
PT
14

GASTROENTEROHEPATOLOGY
GE
20


INTERNAL MEDICINE
BIOMEDICAL
ETHICS&DEONTOLOGY
PHARMACOLOGY
IM
3
3
BED
4
4
PC
4
4



PRAC.
LAB/CSL DISCUSSION TOTAL
1x3=3
17
(2 Groups)
20
PH
4
4
IDCM
4
4

PUBLIC HEALTH
INFECTIOUS DISEASES & CLINICAL
MICROBIOLOGY
BIOSTATISTICS
BS
2

PHYTOTHERAPY
PHY
3
1X2=2
4
3
1X3=3
(4 Groups)

CLINICAL SKILLS LAB
CSL

PATHOPHYSIOLOGY
PP
2
2

FAMILY MEDICINE
FM
2
2

PEDIATRICS
PED
1
1

PEDIATRIC SURGERY
PEDS
1
1

RADIOLOGY
RAD
1
1

MEDICAL GENETICS
MG
1
1

SURGERY
GS
1
1

EMERGENCY MEDICINE
EM
1
1
TOTAL
68
6
3
2
Coordination Committee
HEAD
Cengiz Pata, MD Prof
SECRETARY
Özlem Sönmez , MD Assist. Prof
Ece Genç , MD Prof
Ferda Özkan , MD Prof
Elif Vatanoğlu, MD Assist Prof (Co-coordinator)
MEMBER
MEMBER
MEMBER
50
76
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
GASTROINTESTINAL SYSTEM COMMITTEE IV
LECTURERS
DISCIPLINE
LECTURERS
GASTROENTEROHEPATOLOGY
Cengiz Pata, MD Prof.
Ümit Akyüz, MD Assoc. Prof.
INTERNAL MEDICINE
Yaşar Küçükardalı, MD Prof
PATHOLOGY
Ferda Özkan, MD Prof.
Işın Doğan Ekici, MD Assoc. Prof
PATHOPHYSIOLOGY
Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY
Ece Genç, PhD Prof.
Ferda Kaleağasıoğlu, MD Assoc.Prof
PEDIATRICS
Meltem Uğraş, MD Assist. Prof.
PHYTOTHERAPY
Erdem Yeşilada, MD PhD Prof
PUBLIC HEALTH
Recep Erol Sezer, MD Prof
Hale Arık Taşyıkan, MD Assist. Prof.
FAMILY MEDICINE
CSL
Hülya Akan, MD Assoc. Prof.
Özlem Tanrıöver, MD Assoc. Prof.
Orhan Önder Eren, MD Assist Prof.
Özlem Sönmez, MD Assist Prof
PEDIATRIC SURGERY
Selami Sözübir, MD, Prof.
RADIOLOGY
Bengi Gürses, MD, Assoc. Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL
MICROBIOLOGY
Meral Sömnezoğlu, MD, Assoc. Prof.
Yeşim Gürol, MD, Assoc. Prof.
SURGERY
Özcan Gökçe, MD, Prof.
BIOSTATISTICS
Çiğdem Kaspar, PhD, Assist. Prof
51
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
GASTROINTESTINAL SYSTEM - COMMITTEE IV
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of gastrointestinal system,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency related to gastrointestinal system,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to gastrointestinal system,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or
improvement of health against those clinical conditions related to gastrointestinal system,
5. to convey knowledge on mechanisms of occurrence for frequently encountered clinical
complaints, symptoms, signs and findings in clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to gastrointestinal system,
6. to convey necessary knowledge together with performance measures on health care
processes, clinical decision making process, clinical decisions and clinical practices required for
managing clinical conditions related to gastrointestinal system, which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency, at the level of primary health care service,
7. to convey knowledge on pharmacology of drugs that are effective on gastrointestinal system
or on clinical conditions involving gastrointestinal system,
8. to convey knowledge on phytotherapeutic agents that are effective on gastrointestinal system
or on clinical conditions involving gastrointestinal system,
9. to convey knowledge on biostatistical analysis of association between variables,
10.to convey necessary knowledge on legal regulations and ethical principles for end-of-life
decisions,
11.to equip with basic and advanced clinical skills (approach to patient with gastrointestinal clinical
condition-C4) required at primary health care service level.
52
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.0. recall anatomy, histology and physiology of gastrointestinal system,
2.0. explain etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical
conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
gastrointestinal system,
3.0. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
gastrointestinal system,
4.0. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to gastrointestinal system,
5.0. explain importance of healthy nutrition, principles of balanced diet, and measurement of nutritional
status,
6.0. describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms,
signs and findings in clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to
gastrointestinal system,
7.0. at multi-system level and/or related to gastrointestinal system,
• for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
7.1. practice of history taking and physical examination (gastrointestinal-C4)
7.2. evaluation of emergency case (acute abdominal pain-C4)
7.3. approach to healthy individual or patient (diarrhea-C4)
7.4. laboratory tests/examinations
7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumorsC4)
7.6. point of care testing
7.7. making preliminary diagnosis or definitive diagnosis decision
7.8. making non-intervention or intervention decision
7.9. practicing non-intervention or intervention
7.10. referral/transport of healthy individual or patient
8. list differences of gastrointestinal clinical conditions that may occur in children,
9. explain liver transplantation (indications, contraindications, conditions, risks, methods, patient care,
results and monitorization),
10. explain pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic
agents, prokinetic, laxative and purgative drugs) that are effective on gastrointestinal system or on
clinical conditions involving gastrointestinal system,
11. explain genetics of gastrointestinal system,
12. explain phytotherapeutic agents that are effective on gastrointestinal system or on clinical
conditions involving gastrointestinal system,
13. define biostatistical analysis of association between variables,
14. tell legal regulations and ethical principles for end-of-life decisions,
15. perform basic clinical skills, practiced on phantom models and advanced clinical skills, practiced
on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4),
required at primary health care service.
53
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE IV
GASTROINTESTINAL SYSTEM
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.
1.0.,2.0.,3.0.,4.0.,6.0.,6.0.,7.1.
2.0.,6.0.
2.0.,6.0.
2.0.,3.0.,4.0.,6.0.,7.0.
2.0.,3.0.,4.0.,6.0.,7.3.
2.0.,3.0.,4.0.,6.0.,7.4.
2.0.,3.0.,4.0.,6.0.,7.4.
2.0.,6.0.,7.4.
3.0.,4.0.,5.0.
3.0.,4.0.,5.0.
5.0.
7.3.
7.3.
7.5.
9.0.
10.0.
10.0.
11.0.
13.0.
14.0.
FACULTY
DEPARTMENT
GE
GE
PEDS
IM
PP
PT
IDCM
EM
IDCM
IDCM
PT
PH
PH
PED
FM
FM
RAD
GS
PC
PC
MG
BS
BED
PHR (PHY)
LECTURER/INSTRUCTOR
C. Pata
Ü. Akyüz
S. Sözübir
Y. Küçükardalı
M. Kaçar
I. D. Ekici
M. Sönmezoğlu
S. Sarıkaya
Y. Gürol
G. Çelik
F. Özkan
R.E. Sezer
H.A.Taşyıkan
M. Ugras
H. Akan
Ö. Tanrıöver
B. Gürses
Ö. Gökçe
E. Genç
F. Kaleağasıoğlu
A.Ç. Kuskucu
Ç. Kaspar
E. Vatanoğlu
E. Yeşilada
TOTAL
LEARNING OBJECTIVE
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.
2.0.,6.0.,7.4.
FACULTY
DEPARTMENT
GE
PT
CE
16
9
1
3
3
5
4
1
2
1
16
3
2
1
1
1
1
2
3
2
2
5
3
3
90
LECTURER/INSTRUCTOR
C. Pata
F. Özkan
TOTAL
54
CE
3
2
5
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
5
2
23
3
1
13
0
0
1
1
1
5
1
1
5
2
1
8
1
1
6
0
0
1
1
0
3
0
0
1
5
1
22
0
0
3
1
1
4
0
0
1
0
0
1
0
0
1
1
0
2
0
0
2
1
1
5
0
0
2
0
0
2
1
1
7
1
1
5
1
1
5
25/200
13/100
128
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
3
2
5
-
PHASE III
COMMITTEE IV
GASTROINTESTINAL SYSTEM
I. WEEK
DAY
HOUR
22-Dec-2014
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
23-Dec-2014
TUESDAY
24-Dec-2014
WEDNESDAY
Oral Pathology
Pathology of Esophagus I
Pathology of Esophagus II
F. Özkan
F. Özkan
F. Özkan
I.D. Ekici and
Committee III
Coordination
Committee
Members
Discussion hour for the Committee III exam
questions
Acute Gastroenteritis
Pathology of Stomach I
Pathology of Stomach II
Gastrointestinal Bleedings in Children
M. Sönmezoğlu
F. Özkan
F. Özkan
S. Sözübir
Relation Between Two Variables
Relation Between Two Variables
Organ Transplantation and Ethics I
Organ Transplantation and Ethics II
Ç. Kaspar
Ç. Kaspar
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Relation Between Several Variables
Relation Between Several Variables
Oral and Dental Health
Epidemiology, Prevention and Control of Obesity I
Ç. Kaspar
Ç. Kaspar
Epidemiology, Prevention and Control of Obesity
II
Public Health and Nutrition I
Public Health and Nutrition II
Independent study hours
H.A.Taşyıkan
Jaundice
Malabsorbtion
Clinical Approach to the Patient with Acute
Abdominal Pain
Independent study hours
Ü.Akyüz
C. Pata
Pathology LAB I
Pathology LAB I
Pathology LAB I
Independent study hours
F. Özkan/I.D.Ekici
F. Özkan/I.D.Ekici
F. Özkan/I.D.Ekici
Inflammatory Bowel Disease
Functional GI Disorders & Irritable Bowel Disease
Approach to the Patient with Diarrhea Regarding
to Primary Care
Food Poisoning
C. Pata
C. Pata
15.00-15.50
16.00-16.50
17.00-17.50
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
26-Dec-2014
FRIDAY
LECTURER
E. Vatanoğlu
Y. Küçükardalı
Y. Küçükardalı
M. Kaçar
M. Kaçar
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
14.00-14.50
25-Dec-2014
THURSDAY
SUBJECT
Introduction to Committee IV
Semiology
Semiology
Pathophysiology of Gastro–intestinal Disorders I
Pathophysiology of Gastro–intestinal Disorders II
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Phytotherapy-IV
Phytotherapy-V
Phytotherapy-VI
Independent study hours
55
H.A.Taşyıkan
R.E. Sezer
R.E. Sezer
S. Sarıkaya
H. Akan
Y. Gürol
E. Yeşilada
II. WEEK
DAY
HOUR
SUBJECT
LECTURER
29-Dec-2014
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16:00-16:50
17:00-17:50
Gastritis and Helicobacter Pylori
Peptic Ulcer Disease
Agents used in the Treatment of Peptic Ulcer I
Agents used in the Treatment of Peptic Ulcer II
C. Pata
C. Pata
E. Genç
E. Genç
30-Dec-2014
09.00-09.50
TUESDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Gastroesophageal (GE) Reflux and Esophageal
Motility Disorder
Tumors of Eusophagus, Stomach and Small
Intestine
Pathology of Intestinal Diseases I
Pathology of Intestinal Diseases II
Pathology Lab Group II
Pathology Lab Group II
Pathology Lab Group II
Independent study hours
31-Dec -2014
Independent study day
01-Jan-2015
NEW YEAR HOLIDAY
02-Jan-2015
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
C. Pata
C. Pata
F. Özkan
F. Özkan
F. Özkan/ I.D. Ekici
F. Özkan/ I.D. Ekici
F. Özkan/ I.D. Ekici
Premalignant Lesion of the Colon
Malignant Lesions of the Colon
Hepatitis I
Hepatitis I
C. Pata
C. Pata
G. Çelik
M. Sönmezoğlu
Approach to the Patient with Abdominal Pain
Regarding to Primary Care
The Ethics of Testing and Screening I
The Ethics of Testing and Screening II
Independent study hours
Ö. Tanrıöver
56
E. Vatanoğlu
E. Vatanoğlu
III. WEEK
DAY
HOUR
SUBJECT
LECTURER
05-Jan-2015
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13 33-13 50
14 00-16 50
Clinical Nutrition
Pathology of Appendix & Peritoneum
Chronic Viral Hepatitis
Cirrhosis and Complications
M. Uğraş
F. Özkan
C. Pata
C. Pata
17.00-17.50
06-Jan-2015
TUESDAY
Ü.Akyüz
Ü.Akyüz
F. Özkan
F. Özkan
CSL Group II
(Approach to the patient with gastrointestinal
system disorders)
Independent study hours
O.Ö. Eren
Drug Induced Liver Disease
Mass Lesions of the Liver
Prokinetic, Laxative and Purgative Drugs
Emetic & Antiemetic Agents
C. Pata
C. Pata
F. Kaleağasıoğlu
F. Kaleağasıoğlu
CSL GROUP III
(Approach to the patient with gastrointestinal
system disorders)
Independent study hours
Ö. Sönmez
Acute Liver Failure
Disease of the Bile Duct and Gall Bladder
Pathology of Liver & Biliary System I
Pathology of Liver & Biliary System II
Ü. Akyüz
Ü. Akyüz
I. D. Ekici
I. D. Ekici
CSL Group IV
(Approach to the patient with gastrointestinal
system disorders)
Independent study hours
Ö. Sönmez
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
Acute and Chronic Pancreatitis
Tumors of the Bile Ducts and Pancreas
Alcoholic and Nonalcoholic Liver Disease
Pathology of Liver & Biliary System III
Ü. Akyüz
Ü. Akyüz
Y. Küçükardalı
I.D. Ekici
Pathology of Liver & Biliary System IV
I. D. Ekici
15.00-15.50
Radiology of Gastrointestinal System
16.00-16.50
Transplantation of liver
Complex diseases-Inherited Gastrointestinal
System Disorders
B. Gürses
Ö. Gökçe
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
08-Jan-2015
THURSDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
09-Jan-2015
FRIDAY
O.Ö. Eren
Otoimmun Hepatitis
Wilson Disease and Hemochromatisis
Pathology of Liver I
Pathology of Liver II
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
07-Jan-2015
WEDNESDAY
CSL GROUP I
(Approach to the patient with gastrointestinal
system disorders)
Independent study hours
17.00-17.50
57
A.Ç. Kuşkucu
IV. WEEK
12-Jan-2015
MONDAY
09.00-17.50
Independent study hours
13-Jan-2015
TUESDAY
09.00-17.50
Independent study hours
14-Jan-2015
WEDNESDAY
09.00-17.50
Independent study hours
15-Jan-2015
10.0013.00
COMMITTEE EXAM
09:0018:00
OSCE-I EXAM
THURSDAY
16-Jan-2015
FRIDAY
19 January – 30 January 2015
58
MIDTERM BREAK
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
DISTRIBUTION of LECTURE HOURS
February 2, 2015 – February 27,2015
COMMITTEE DURATION: 4 WEEKS

DISCIPLINE

PATHOLOGY

OBST & GYNEC

ENDOCRINOLOGY

ABBR.
THEO.
PRAC.
LAB/CSL
DISCUSSION TOTAL
PT
OBSGYN
END
20
20
16
16
13
13
INTERNAL MEDICINE
IM
2
2

PHARMACOLOGY
PC
11
11


MG
6

MEDICAL GENETICS
INFECTIOUS DISEASES & CLINICAL
MICROBIOLOGY
PATHOPHYSIOLOGY

6
1x2=2
(2 Groups)
5
IDCM
3
PP
5
BIOSTATISTICS
BS
2

PUBLIC HEALTH
PH
4
4

FAMILY MEDICINE
FM
4
4

PEDIATRICS
PED
3
3

CLINICAL SKILLS LAB
CSL

PHYTOTHERAPY

RADIOLOGY
PHR
(PHY)
RAD

HISTOLOGY


SCIENTIFIC PROJECTS- III
BIOMEDICAL
ETHICS&DEONTOLOGY
TOTAL
5
1X2=2
1x3=3
(4 Groups)
3
2
2
1
1
HST
1
1
SP
1
1
4
4
98
5
Coordination Committee
HEAD
Cem Fıçıcıoğlu, MD Prof
SECRETARY
Oluş Api, MD Assoc. Prof.
MEMBER
Hasan Aydın, MD Assoc. Prof.
MEMBER
Gülay Çiler Erdağ, MD Assist. Prof.
Ayşegül Ç. Kuşkucu, MD PhD Assist Prof
(Co-coordinator)
MEMBER
4
59
2
105
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
LECTURERS
DISCIPLINE
LECTURERS
OBSTETRICS and GYNECOLOGY
N. Cem Fıçıcıoğlu, MD Prof.
Oluş Api, MD Assoc. Prof.
Rukset Attar, MD Assoc. Prof.
Gazi Yıldırım, MD Assoc. Prof.
ENDOCRINOLOGY
Hasan Aydın, MD Assoc. Prof.
INTERNAL MEDICINE
Yaşar Küçükardalı, MD Prof.
PATHOLOGY
Ferda Özkan, MD Prof.
Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY
Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY
Ece Genç, PhD Prof.
Ferda Kaleağasıoğlu, MD Assoc. Prof.
PEDIATRICS
Gülay Çiler Erdağ, MD Assist. Prof.
PUBLIC HEALTH
Recep Erol Sezer, MD Prof.
Hale Arık Taşyıkan, MD Assist. Prof.
PHYTOTHERAPY
Erdem Yeşilada, MD PhD Prof.
FAMILY MEDICINE
CLINICAL SKILLS LAB
Özlem Tanrıöver, MD Assoc. Prof.
Ayşe Arzu Akalın, MD Assist. Prof.
Rukset Attar, MD Assoc. Prof.
Gazi Yıldırım, MD Assoc. Prof.
Oluş Api, MD Assoc. Prof.
RADIOLOGY
Bengi Gürses, MD Assoc. Prof.
Ali Özgen,MD
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL
Gulden Çelik, MD Prof.
Meral Sönmezoğlu, MD Assoc. Prof.
Yeşim Gürol , MD Assoc. Prof.
MICROBIOLOGY
BIOSTATISTICS
Çiğdem Kaspar, PhD Assist. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY Elif Vatanoğlu, MD PhD Assist. Prof.
SCIENTIFIC PROJECTS- III
Gülderen Yanıkkaya Demirel, MD Assoc. Prof.
60
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1.
to remind knowledge on anatomy, embryology, histology and physiology of endocrine and
reproductive systems,
2. to convey knowledge on health care service practices related to reproductive care,
3. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to endocrine and reproductive systems,
4. to convey knowledge on epidemiology of clinical conditions which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency
related to endocrine and reproductive systems,
5. to convey necessary knowledge on prevention of clinical conditions, and protection or
improvement of health against those clinical conditions related to endocrine and reproductive
systems,
6. to convey knowledge on mechanims of occurence for frequently encountered clinical complaints,
symptoms, signs and findings in clinical conditions which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency
related to endocrine and reproductive systems,
7. to convey necessary knowledge together with performance measures on health care processes,
clinical decision making process, clinical decisions and clinical practices required for managing
clinical conditions related to endocrine and reproductive systems, which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency, at the level of primary health care service,
8. to convey knowledge on pharmacology of drugs that are effective on endocrine and reproductive
systems or on clinical conditions involving endocrine and reproductive systems,
9. to convey knowledge on genetics of endocrine and reproductive systems,
10. to convey knowledge on phytotherapeutic agents that are effective on endocrine system or on
clinical conditions involving endocrine system,
11. to convey knowledge on design and biostatistical analysis of survival research,
12. to convey knowledge on legal regulations and ethical principles related to reproductive care,
13. to equip with basic and advanced clinical skills (normal spontaneous vaginal delivery on phantom
model-C5) required at primary health care service level.
61
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.0.
2.0.
3.0.
4.0.
recall anatomy, embryology, histology and physiology of endocrine and reproductive systems,
explain physiology of normal spontaneous vaginal delivery,
define practice of reproductive care,
explain
etiopathogenesis
of
clinical
conditions
(menstrual
cycle/developmental
conditions/congenital and sexually transmitted infections) which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency
related to endocrine and reproductive systems,
5.0. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
endocrine and reproductive systems,
6.0. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to endocrine and reproductive systems,
7.0. describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms,
signs and findings in clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to
endocrine and reproductive systems,
8.0. at multi-system level and/or related to endocrine and reproductive systems,
• for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)
8.2. evaluation of emergency case
8.3. approach to healthy individual or patient (pregnancy-C5)
8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum
sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening
[antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)
8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5,
radioisotope imaging of thyroid and parathyroid-C5)
8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)
8.7. making preliminary diagnosis or definitive diagnosis decision
8.8. making non-intervention or intervention decision
8.9. practicing non-intervention or intervention
8.10. referral/transport of healthy individual or patient
9.0. explain pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions
and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs,
insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on
endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive
systems,
10.0. explain genetics of endocrine and reproductive systems,
11.0. explain mechanisms of action for phytotherapeutic agents that are effective on endocrine
system or in clinical conditions related to endocrine system,
12.0. define design and biostatistical analysis of survival research,
13.0. explain legal regulations and ethical principles related to reproductive care,
14.0.
perform basic clinical skills, practiced on phantom models (normal spontaneous vaginal
delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required
at primary health care service.
62
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE V
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0
1.0-8.0
1.0-8.0
1.0-8.0
1.0-8.0
1.0, 4.0-8.0
1.0, 4.0-8.0
1.0, 4.0, 7.0, 8.4
1.0, 4.0, 7.0, 8.4
4.0, 5.0, 6.0, 7.0, 8.0
4.0, 5.0, 6.0, 7.0, 8.4
4.0, 7.0
5.0, 6.0
5.0, 6.0
6.0, 8.0,8.1, 8.3
8.3
8.5
9.0
9.0
10.0
12.0
10.0
FACULTY
DEPARTMENT
LECTURER/INSTRUCTOR
CE
1
5
5
4
3
13
4
12
3
1
2
4
1
2
3
1
1
5
5
5
3
HST
OBS-GYN
OBS-GYN
OBS-GYN
OBS-GYN
END
PED
PT
PT
IDCM
IDCM
PP
PH
PH
FM
FM
RAD
PC
PC
MG
BS
O. Akçin
C. Fıçıcıoglu
O. Api
R. Attar
G.Yıldırım
H. Aydın
G.Ç. Erdag
F. Özkan
I.D. Ekici
M. Sönmezoglu
G. Çelik
M. Kaçar
R.E. Sezer
H.A.Taşyıkan
A Akalın
Ö. Tanrıöver
B. Gürses /A.Özgen
E. Genç
F.Kaleagasıoglu
A. Ç. Kuskucu
Ç. Kaspar
PHR (PHY)
E. Yesilada
2
BED
E. Vatanoğlu
4
89
TOTAL
LEARNING OBJECTIVE
1.0, 4.0-8.0
1.0-8.0
1.0, 4.0, 7.0, 8.4
FACULTY
DEPARTMENT
END
OBS-GYN
PT
LECTURER/INSTRUCTOR
H. Aydın
O.Api
F. Özkan
TOTAL
63
CE
2
2
1
5
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
0
0
1
2
1
8
1
1
7
1
0
5
1
0
4
3
2
18
1
0
5
1
1
14
2
1
6
0
0
1
1
0
3
1
1
6
1
0
2
0
1
3
1
0
4
0
0
1
0
0
1
2
1
8
1
1
7
2
1
8
1
0
4
1
0
3
2
1
7
25/200
12/100
126
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
2
2
1
5
-
PHASE III COMMITTEE V
ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS
I. WEEK
DAY
HOUR
02-Feb-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
SUBJECT
Introduction to Committee V
Introduction to Endocrinology
Hyperfunctioning Disorders of Anterior
Pituitary Gland
Pathology of Endocrine System: Introduction
Pathophysiology of Endocrine System
Diseases I
LECTURER
A.Ç. Kuşkucu
H. Aydın
H. Aydın
F. Özkan
M. Kaçar
13.00-13.50
14.00-14.50
15.00-15.50
04-Feb-2015
WEDNESDAY
05-Feb-2015
THURSDAY
06-Feb-2015
FRIDAY
M. Kaçar
M. Kaçar
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Disorders of Posterior Pituitary Gland
Hypopituatirism
Thyroid Disorders
Introduction to Endocrine Pharmacology
C. Pata and Committee
IV Coordination
Committee members
H. Aydın
H. Aydın
H. Aydın
E. Genç
Design of Survival Studies
Design of Survival Studies
Reproductive Ethics I
Reproductive Ethics II
Ç. Kaspar
Ç. Kaspar
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Hypothalamic and Pituitary Hormones I
Hypothalamic and Pituitary Hormones II
Thyroid Function Tests
Imaging of Thyroid Glands
F. Kaleağasıoğlu
F. Kaleağasıoğlu
H. Aydın
B. Gürses/ A.Özgen
Pathologyof Thyroid & Parathyroid I
Pathology of Thyroid & Parathyroid II
Analysis of Survival Times
Analysis of Survival Times
F. Özkan
F. Özkan
Ç. Kaspar
Ç. Kaspar
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Calcium Metabolism
Hypercalcemic Diseases
Hypocalcemic Diseases
Pathology of Adrenal Gland I
H. Aydın
H. Aydın
H. Aydın
F. Özkan
Pathology of Adrenal Gland II
Congenital Adrenal Hyperplasia
Scientific Projects- III (Writing Project)
Independent study hours
F. Özkan
G.Ç. Erdağ
G.Y. Demirel
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Reproductive, Maternal and Child Health I
Reproductive, Maternal and Child Health II
Inborn Errors of Metabolism I
Inborn Errors of Metabolism II
H.A.Taşyıkan
H.A.Taşyıkan
A.Ç. Kuşkucu
A.Ç. Kuşkucu
Reproductive Ethics III
Reproductive Ethics IV
E. Vatanoğlu
E. Vatanoğlu
16.00-17.50
03-Feb-2015
TUESDAY
Pathophysiology of Endocrine System
Diseases II
Pathophysiology of Endocrine System
Diseases III
Discussion hour for the Committee IV
exam questions
Independent study hours
64
II. WEEK
DAY
HOUR
SUBJECT
LECTURER
09-Feb-2015
09.00-09.50
Y. Küçükardalı
MONDAY
10.00-10.50
Introduction to Diabetes Mellitus
Clinical and Laboratory Findings of Diabetes
Mellitus
Thyroid and Antithyroid Drugs I
Thyroid and Antithyroid Drugs II
Pathology of Pituitary Gland I
Pathology of Pituitary Gland II
Phytotherapy-VII
Phytotherapy-VIII
I.D. Ekici
I.D. Ekici
Hypoglycemia
Adrenocortical Hormones and Drugs I
Adrenocortical Hormones and Dugs II
Pathology of Pancreas I
H. Aydın
E. Genç
E. Genç
I.D. Ekici
Pathology of Pancreas II
Reproductive, Maternal and Child Health III
Epidemiology, Prevention and Control of
Type II Diabetes Mellitus
Independent study hours
I.D. Ekici
H.A.Taşyıkan
Adrenal Disorders
Obesity
Diffuse Hormonal Systems and Endocrine
Tumor Syndromes
Insulin and Oral Antidiabetic Drugs I
H. Aydın
H. Aydın
Insulin and Oral Antidiabetic Drugs II
Independent study hours
Independent study hours
Independent study hours
E. Genç
Pathophysiology of Reproductive System
Diseases
Pathophysiology of Reproductive System
Diseases
Pathology of Breast I
Pathology of Breast II
M. Kaçar
Chromosomal Disorders I
Chromosomal Disorders II (Sex
chromosomes and their abnormalities)
Independent study hours
Independent study hours
A. Ç. Kuşkucu
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
10-Feb-2015
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
11-Feb-2015
WEDNESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
12-Feb-2015
09.00-09.50
THURSDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
13-Feb-2015
FRIDAY
Y. Küçükardalı
E. Genç
E. Genç
E.Yeşilada
R.E. Sezer
H. Aydın
E. Genç
M. Kaçar
F. Özkan
F. Özkan
A.Ç. Kuşkucu
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Independent study hours
Pathology of Vulva & Vagina
Pathology of Cervix Uteri I
Pathology of Cervix Uteri II
F. Özkan
F. Özkan
F. Özkan
CSL GROUP IV
(Stages of normal labour)
R.Attar /G. Yıldırım/
O. Api
17.00-17.50
Independent study hours
65
III. WEEK
DAY
16-Feb-2015
MONDAY
HOUR
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
17-Feb-2015
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
18-Feb-2015
09.00-09.50
WEDNESDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
19-Feb-2015
09.00-09.50
THURSDAY
10.00-10.50
11.00-11.50
12.00-12.50
SUBJECT
Antenatal Care
Embryology
Medical History for Breast Diseases in
Primary Care BSE & Clinical Breast
Examination
Genetic disorders of gonadal development
LECTURER
O. Api
O. Akçin
A. Akalın
Prenatal genetic diagnosis and genetic
counseling
Mıcrobıology laboratory (Diagnostic tests
of urogenital specimens) GROUP I-II
Independent study hours
A.Ç. Kuşkucu
The Gynecological History and Examination
Conditions affecting Vulva & Vagina
Delivery of Family Planning Services I
Delivery of Family Planning Services II
G.Yıldırım
G.Yıldırım
A. Akalın
A. Akalın
General Approach to the Pregnant Woman
Normal Pubertal Development
Pubertal Disorders
Independent study hours
Ö. Tanrıöver
G.Ç. Erdağ
G.Ç. Erdağ
The Menstrual Cycle and Disorders of the
Menstrual Cycle
Normal and Abnormal Sexual Development
& Puberty
Estrogens, Progestines and Inhibitors I
Estrogens, Progestines and Inhibitors II
R. Attar
Normal and abnormal labor
Mıcrobıology laboratory (Diagnostic tests
of urogenital specimens) GROUP III-IV
Independent study hours
O. Api
İ.Ç.Acuner/
Y.Gurol/G.Çelik
Disorders of Early Pregnancy (Miscarriage;
Ectopic; GTD)
Pathology of Pregnancy & Placenta
Congenital Infections and Sexually
Transmitted Diseases, Genital Infections I
Congenital Infections and Sexually
Transmitted Diseases, Genital Infections II
O. Api
Congenital Infections and Sexually
Transmitted Diseases, Genital Infections
Independent study hours
M. Sönmezoğlu
Endometriosis & Adenomyosis
Puerperal Infections
Pathology of Treponemal Infections
Pathology of Uterus I
G. Yıldırım
O. Api
F. Özkan
F. Özkan
Pathology of Uterus II
CSL GROUP II (Stages of normal labour)
F. Özkan
R.Attar /G. Yıldırım/
O. Api
A.Ç. Kuşkucu
İ.Ç.Acuner/
Y.Gurol/G.Çelik
R. Attar
F. Kaleağasıoğlu
F. Kaleağasıoğlu
F. Özkan
G. Çelik
G. Çelik
13.00-13.50
14.00-14.50
15.00-17.50
20-Feb-2015
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-17.50
66
IV. WEEK
DAY
HOUR
SUBJECT
Benign Diseases of the Uterus and the
Cervix
Benign Diseases of the Ovary
Malign Diseases of the Ovary
Malign Diseases of the Uterus & Cervix
LECTURER
23-Feb-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-17.50
Pathology of Ovary I
Pathology of Ovary I
Independent study hours
F. Özkan
F. Özkan
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Menopause
Fertility Control
Infertility
Independent study hours
C. Fıçıcıoğlu
C. Fıçıcıoğlu
C. Fıçıcıoğlu
CSL GROUP I
(Stages of normal labour)
R. Attar / G. Yıldırım /
O. Api
17.00-17.50
Independent study hours
25- Feb-2015
WEDNESDAY
09.00-17.50
Independent study hours
26-Feb-2015
THURSDAY
09.00-17.50
Independent study hours
27-Feb-2015
FRIDAY
10.00-13.00
COMMITTEE EXAM
24-Feb-2015
TUESDAY
67
R. Attar
R. Attar
G.Yıldırım
G.Yıldırım
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
URINARY SYSTEM
COMMITTEE VI
DISTRIBUTION of LECTURE HOURS
March 02, 2015 – March 27 , 2015
COMMITTEE DURATION: 4 WEEKS

DISCIPLINE

UROLOGY

ABBR.
THEO.
URO
7
7
NEPHROLOGY
NE
15
15

PATHOLOGY
PT
12

PATHOPHYSIOLOGY
PP
2
2

PHARMACOLOGY
PC
3
3

PEDIATRICS
PED
1
1

PUBLIC HEALTH
PH
2

CLINICAL SKILLS LAB
CSL

RADIOLOGY
RAD


MG
MEDICAL GENETICS
INFECTIOUS DISEASES & CLINICAL
IDCM
MICROBIOLOGY
PED-S
PEDIATRIC SURGERY

PRAC.
LAB/CSL
DISCUSSION TOTAL
1x2=2
(2 Groups)
14
2
1x2=2
(4 Groups)
1x3=3
(4 Groups)
1
1
1
1
2
1x2=2
(2 Groups)
4
1
1
1
1

GENERAL SURGERY
GS

BIOSTATISTICS
BS
2

FAMILY MEDICINE
FM
1
TOTAL
5
51
1x2=2
1
9
2
Coordination Committee
HEAD
Gülçin Kantarcı , MD, Prof
SECRETARY
Hakan Koyuncu , MD, Assist. Prof
Selami Sözübir, MD, Prof.
Zehra Eren, MD, Assoc. Prof
Özlem Tanrıöver, MD Assoc Prof (Co-coordinator)
MEMBER
MEMBER
MEMBER
68
4
62
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
URINARY SYSTEM
COMMITTEE VI
LECTURERS
DISCIPLINE
LECTURERS
UROLOGY
Faruk Yencilek, MD Assoc. Prof.
Ahmet Tunç Özdemir, MD Assoc. Prof.
Hasbey Hakan Koyuncu, MD Assist. Prof.
NEPHROLOGY
Gülçin Kantarcı, MD Prof.
Zehra Eren, MD Assist. Prof.
PATHOLOGY
Ferda Özkan, MD Prof.
Işın Doğan Ekici MD, Assoc. Prof.
PATHOPHYSIOLOGY
Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY
Ece Genç, PhD Prof.
PEDIATRICS
Ayça Vitrinel, MD Prof.
Filiz Bakar , MD Prof.
PUBLIC HEALTH
Hale Arık Taşyıkan, MD Assist. Prof.
CLINICAL SKILLS LAB
Rukset Attar, MD Assoc. Prof.
Gazi Yıldırım, MD Assoc. Prof.
Oluş Api, MD Assoc. Prof.
Güldal İzbırak, MD, Assoc. Prof.
Ayşe Arzu Akalın, MD Assist. Prof.
Gülay Çiler Erdağ, MD Assist. Prof.
Defne Çöl,MD Assist. Prof.
RADIOLOGY
Bengi Gürses, MD Assoc. Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu,MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL
MICROBIOLOGY
Gülden Çelik, MD, Prof.
Yeşim Gürol, MD, Assoc. Prof
Ibrahim Çağatay Acuner, MD, Assoc. Prof
Meral Sönmezoğlu, MD, Assoc. Prof.
PEDIATRIC SURGERY
Selami Sözübir, MD, Prof.
GENERAL SURGERY
Özcan Gökçe, MD, Prof.
BIOSTATISTICS
Çiğdem Kaspar, PhD, Assist. Prof.
FAMILY MEDICINE
Hülya Akan, MD Assoc. Prof.
69
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
URINARY SYSTEM
COMMITTEE VI
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of urinary system,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to urinary system,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency
related to urinary system,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or improvement
of health against those clinical conditions related to urinary system,
5. to convey knowledge on mechanims of occurence for frequently encountered clinical complaints,
symptoms, signs and findings in clinical conditions which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency
related to urinary system
6. to convey necessary knowledge together with performance measures on health care processes,
clinical decision making process, clinical decisions and clinical practices required for managing
clinical conditions related to urinary system, which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency, at the level
of primary health care service,
7. to convey knowledge on pharmacology of drugs that are effective on urinary system or on clinical
conditions involving urinary system,
8. to convey knowledge on genetics of urinary system,
9. to convey knowledge on phytotherapeutic agenst that are effective on urinary system or on clinical
conditions involving urinary system,
10. to convey knowledge on use of biostatistical software and presentation of results,
11. to convey knowledge on legal regulations and ethical principles related to reproductive care,
12. to equip with basic and advanced clinical skills (gynecological examination-C6, “Pap-smear”
collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in
neonate, infant and prepubertal/pubertal child-C6) required at primary health care service level.
70
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.
2.
recall anatomy, histology and physiology of urinary system,
explain etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal
clinical conditions, urinary system stones, urinary system infections) which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency related to urinary system,
3. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
cardiovascular and respiratory systems,
4. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to urinary system,
5. describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms,
signs and findings in clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to urinary
system,
6. at multi-system level and/or related to urinary system,
• for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
6.2. evaluation of emergency case (urological emergencies-C6)
6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6,
fecal specimen collection-C6)
6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7. explain pharmacology of drugs that are effective on urinary system or on clinical conditions
involving urinary system,
8. explain pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral
homeostasis,
9. explain genetics of urinary system,
10. explain mechanisms of action for action for phytotherapeutic agents that are effective on urinary
system or in clinical conditions related to urinary system,
11. define use of biostatistical software and presentation of results,
12. perform basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced
on simulated/standardized patients (gynecological examination-C6, “Pap-smear” collection-C6,
intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant
and prepubertal/pubertal child-C6), required at primary health care service.
71
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE VI
URINARY SYSTEM
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0., 2.0., 5.0., 6.4.
2.0., 5.0.
2.0.-6.0.
2.0.-5.0., 6.4.
3.0., 4.0.
6.3.
6.5.
7.0., 8.0.
9.0.
11.0.
FACULTY
DEPARTMENT
GS
NE
NE
PED
PED-S
URO
URO
URO
PT
PP
IDCM
IDCM
PH
FM
RAD
PC
MG
BS
LECTURER/INSTRUCTOR
Ö. Gökçe
G. Kantarcı
Z. Eren
A. Vitrinel
S. Sözübir
F. Yencilek
H . Koyuncu
A.T.Özdemir
I D. Ekici
M. Kaçar
M. Sönmezoglu
G. Çelik
H. A. Taşyıkan
H. Akan
B.Gürses
E. Genç
A.Ç. Kuskucu
Ç. Kaspar
TOTAL
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
1.0., 2.0., 5.0., 6.4.
FACULTY
DEPARTMENT
URO
NE
PT
CE
2
14
7
2
2
5
3
4
21
2
3
3
3
2
2
5
3
7
90
LECTURER/INSTRUCTOR
A.T.Özdemir
G. Kantarci
I D. Ekici
TOTAL
72
CE
2
2
1
5
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
0
0
2
4
2
20
3
1
11
1
0
3
1
0
3
1
1
7
1
1
5
1
1
6
6
3
30
1
0
3
1
0
3
0
0
3
1
1
5
1
0
3
0
0
2
1
1
7
0
0
3
2
1
10
25/200
12/100
126
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
2
2
1
5
-
PHASE III
COMMITTEE VI
URINARY SYSTEM
I. WEEK
DAY
HOUR
02-Mar-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
03-Mar-2015
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
04-Mar-2015
WEDNESDAY
05-Mar-2015
THURSDAY
LECTURER
M. Kaçar
M. Kaçar
I D. Ekici
I D. Ekici
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Urolithiasis-I
Urolithiasis-II
Pathology of Male Genital System I
Pathology of Male Genital System II
F. Yencilek
F. Yencilek
I. D. Ekici
I. D. Ekici
Urinary Findings
Nephritic Syndrome
Nephrotic Syndrome
G. Kantarcı
G. Kantarcı
G. Kantarcı
C. Fıçıcıoğlu and
Committee V Coordination
Committee members
Discussion hour for the Committee V
exam questions
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Pathology of Tubulointerstitial Disease I
Pathology of Tubulointerstitial Disease II
Tubulointerstitial Diseases I
Tubulointerstitial Diseases I
I. D. Ekici
I. D. Ekici
G. Kantarcı
G. Kantarcı
Using Statistical Programs
Using Statistical Programs
Independent study hours
Independent study hours
Ç. Kaspar
Ç. Kaspar
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Acute Kidney Injury I
Acute Kidney Injury II
Pathology of Glomerular Diseases I
Pathology of Glomerular Diseases II
G. Kantarcı
G. Kantarcı
I D. Ekici
I D. Ekici
17.00-17.50
06-Mar-2015
FRIDAY
SUBJECT
Introduction to Committee VI
Pathophysiology of Urinary System
Diseases I
Pathophysiology of Urinary System
Diseases II
Renovascular Pathology
Renal Cystic Disease
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
CSL Group I (Gynecological examination,
PAP smear obtaining / Physical
examination of breast and breast self
exam)
Independent study hours
R. Attar/G.Yıldırım/O.Api/
A. Akalın/ G.İzbırak
Upper and Lower Urinary Tract Infections I
Upper and Lower Urinary Tract Infections I
Nephritic and Nephrotic Syndrome
Approach to the Urinary Tract Infections
G. Çelik
M. Sönmezoğlu
A. Vitrinel
H. Akan
Urologic Oncology-I
Urologic Oncology-II
Independent study hours
Independent study hours
A.T. Özdemir
A.T. Özdemir
73
II. WEEK
DAY
09-Mar-2015
MONDAY
10-Mar-2015
TUESDAY
HOUR
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
SUBJECT
Fluid, Electrolyte & Acid/Base Balance I
Fluid, Electrolyte & Acid/Base Balance II
Pathology of Glomerular Diseases III
Pathology of Bladder
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Fluid, Electrolyte & Acid/Base Balance III
Fluid, Electrolyte & Acid/Base Balance IV
Congenital Anomalies of Urinary System
Pathology of Urinary System Tumors
17.00-17.50
11-Mar-2015
WEDNESDAY
09.00-09.50
10.00-10.50
CSL Group III (Gynecological
examination, PAP smear obtaining /
Physical examination of breast and breast
self exam)
Independent study hours
E. Yeşilada
Z. Eren
Z. Eren
I.D. Ekici
I.D. Ekici
R. Attar/ G.Yıldırım/ O.Api/
A.Akalın/ G.İzbırak
Benign Prostatic Hyperplasia-I
Benign Prostatic Hyperplasia-II
Congenital Anomalies of The Urinary
System
Transplantation of Kidney
H. Koyuncu
H. Koyuncu
CSL Group IV (Gynecological
examination, PAP smear obtaining /
Physical examination of breast and breast
self exam)
Independent study hours
R. Attar/ G.Yıldırım/ O.Api/
A. Akalın/ G. İzbırak
Microbiology laboratory (Diagnostic
tests for urinary specimens) GROUP I-II
Microbiology laboratory (Diagnostic
tests for urinary specimens) GROUP IIIIV
İ.Ç. Acuner/ Y. Gurol/ G.
Çelik
H.A.Taşyıkan
16.00-17.50
Epidemiology, Prevention and Control of
Sexually Transmitted Diseases
Epidemiology, Prevention and Control of
Sexually Transmitted Diseases
Independent study hours
09.00-17.50
Independent study hours
11.00-11.50
12.00-12.50
13.00-13.50
4.00-16.50
17.00-17.50
12-Mar-2015
THURSDAY
PHYTOTHERAPY-IV
PHYTOTHERAPY-V
PHYTOTHERAPY-VI
Independent study hours
LECTURER
Z. Eren
Z. Eren
I.D. Ekici
I.D. Ekici
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
S. Sözübir
Ö. Gökçe
İ.Ç. Acuner/ Y.Gurol/
G. Çelik
13.00-13.50
14.00-14.50
15.00-15.50
13-Mar-2015
FRIDAY
74
H.A.Taşyıkan
III. WEEK
DAY
16-Mar-2015
HOUR
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
17.00-17.50
17-Mar-2015
TUESDAY
18-Mar-2015
WEDNESDAY
CSL Group II (Gynecological
examination, PAP smear obtaining /
Physical examination of breast and breast
self exam)
Independent study hours
R. Attar/ G. Yıldırım/
O. Api/
A. Akalın/ G. İzbırak
E. Genç
E. Genç
E. Genç
B. Gürses
Independent study hours
Pathology Group I
Pathology Group II
Independent study hours
F. Özkan/ I.D. Ekici
09.00-09.50
10.00-10.50
Urologic Emergencies
Polygenic disorders
The Kidney Systemic Disease and
İnherited Disorders I
The Kidney Systemic Disease and
İnherited Disorders II
F.Yencilek
A.Ç. Kuşkucu
CSL Group IV (Physical examination of
the newborn and child patient)
CSL Group III (Physical examination of
the newborn and child patient)
G.Ç. Erdağ/ D.Çöl
The presentation of the results
The presentation of the results
Chronic Kidney Disease I
Chronic Kidney Disease II
Ç. Kaspar
Ç. Kaspar
G. Kantarcı
G. Kantarcı
CSL Group II (Physical examination of
the newborn and child patient)
CSL Group I (Physical examination of the
newborn and child patient)
G.Ç. Erdağ/ D. Çöl
12.00-12.50
13.00-13.50
14.00-15.50
16.00-17.50
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-15.50
16.00-17.50
20-Mar-2015
FRIDAY
LECTURER
09.00-09.50
10.00-11.50
12.00-12.50
13.00-14.50
15.00-17.50
11.00-11.50
19-Mar-2015
THURSDAY
SUBJECT
Agents Effecting Bone Mineral
Homeostasis I
Agents Effecting Bone Mineral
Homeostasis II
Androgens & Anabolic Steroids
Imaging of Urinary System
09.00-17.50
Independent study hours
75
F. Özkan/ I.D. Ekici
Z. Eren
Z. Eren
G.Ç. Erdağ/ D.Çöl
G.Ç. Erdağ/ D. Çöl
IV. WEEK
DAY
HOUR
SUBJECT
23-Mar-2015
MONDAY
09.00-17.50
Independent study hours
24-Mar-2015
TUESDAY
09.00-17.50
Independent study hours
25-Mar-2015
WEDNESDAY
09.00-17.50
Independent study hours
26-Mar-2015
THURSDAY
09.00-17.50
Independent study hours
10:00-13:00
COMMITTEE EXAM
27-Mar-2015
FRIDAY
LECTURER
76
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
DISTRIBUTION of LECTURE HOURS
MARCH 30, 2015 – May 08 , 2015
COMMITTEE DURATION: 6 WEEKS

DISCIPLINE

ABBR.
THEO.
PRAC.
1x4=4
(2 Groups)
LAB/CSL
DISCUSSION TOTAL
NEUROLOGY
NR
13

PSYCHIATRY
PCH
12
12

CHILD PSYCHIATRY
C-PCH
3
3

NEUROSURGERY
NRS
16

PATHOLOGY
PT
11

PATHOPHYSIOLOGY
PP
2
2

PHARMACOLOGY
PC
14
14

PEDIATRICS
PED
4
4

PUBLIC HEALTH
PH
5
5

FAMILY MEDICINE
FM
4
17
1x2=2
(2 Groups)
18
1x2=2
(2 Groups)
13
4
2x3=6
(4 Groups)

CLINICAL SKILLS LAB
CSL

RADIOLOGY
RAD
1
1


MG
3
3
IDCM
2
2
OPT
3
3
ANS
2
2

MEDICAL GENETICS
INFECTIOUS DISEASES &
CLINICAL MICROBIOLOGY
OPHTALMOLOGY
ANESTHESIOLOGY &
REANIMATION
BIOISTATISTICS
BS
2

SCIENTIFIC PROJECTS- III


TOTAL
SP
6
1x2=2
4
2
114
1
1
98
6
8
Coordination Committee
HEAD
Başar Atalay, MD, Prof
SECRETARY
Oğuzhan Zahmacıoğlu, MD, Assist. Prof.
Burcu Örmeci, MD, Assist. Prof.
Elif Vatanoğlu, MD, Assist. Prof
(Co-coordinator)
MEMBER
MEMBER
77
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
LECTURERS
DISCIPLINE
LECTURERS
NEUROLOGY
Berrin Aktekin, MD, Prof.
Burcu Örmeci, MD, Assist. Prof.
PSYCHIATRY
N. Berfu Akbaş, MD, Assist. Prof.
Hakan Atalay, MD, Assoc. Prof.
CHILD PSYCHIATRY
Oğuzhan Zahmacıoğlu, MD, Assist. Prof
NEUROSURGERY
M.Gazi Yaşargil, MD, Prof.
Uğur Türe, MD, Prof.
Başar Atalay, MD, Prof.
PATHOLOGY
Ferda Özkan, MD, Prof
Işın Doğan Ekici, MD, Assoc. Prof.
PATHOPHYSIOLOGY
Mehtap Kaçar, MD PhD, Assist. Prof.
PHARMACOLOGY
Ece Genç, PhD, Prof.
Ferda Kalağasıoğlu, MD Assoc. Prof.
PEDIATRICS
Ayça Vitrinel, MD, Prof.
Reha Cengizlier, MD, Prof.
PUBLIC HEALTH
Recep Erol Sezer, MD, Prof
CLINICAL SKILLS LAB
FAMILY MEDICINE
Uğur Anıl Bingöl, MD Assist. Prof
Turhan Özler MD, Assist. Prof
Hakan Koyuncu, MD Assist. Prof
N. Berfu Akbaş, MD Assist. Prof
Oğuzhan Zahmacıoğlu, MD Assist. Prof
Burcu Örmeci, MD Assist. Prof.
Güldal İzbırak, MD, Assoc. Prof.
Özlem Tanrıöver, MD, Assoc. Prof
Hülya Akan, MD, Assoc. Prof.
Ayşe Arzu Akalın, MD, Assist. Prof
RADIOLOGY
Ayşegül Sarsılmaz, MD Assist.Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL
Gülden Çelik, MD, Prof
Meral Sönmezoğlu, MD, Assoc. Prof.
MICROBIOLOGY
OPHTALMOLOGY
Canan Aslı Yıldırım, MD, Assoc. Prof.
Vildan Öztürk, MD, Assist. Prof.
ANESTHESIOLOGY & REANIMATION
Özge Köner, MD, Prof.
BIOSTATISTICS
Çiğdem Kaspar, PhD, Assist. Prof.
SCIENTIFIC PROJECTS- III
Gülderen Yanıkkaya Demirel, MD Assoc. Prof.
78
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of nervous system,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency related to nervous system and psychiatry,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to nervous system and psychiatry,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or
improvement of health against those clinical conditions related to nervous system and
psychiatry,
5. to convey knowledge on mechanims of occurence for frequently encountered clinical
complaints, symptoms, signs and findings in clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to nervous system and psychiatry,
6. to convey necessary knowledge together with performance measures on health care
processes, clinical decision making process, clinical decisions and clinical practices required for
managing clinical conditions related to nervous system and psychiatry, which are frequent in
community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency, at the level of primary health care service,
7. to convey necessary knowledge on drugs that are effective on nervous system or on clinical
conditions related to nervous system and psychiatry ,
8. to convey necessary knowledge on professional standards, organizational ethics, and ethics
of psychiatry,
9. to convey necessary knowledge on common problems in medical research,
10. to convey knowledge on phytotherapeutic agents,
11. to equip with basic and advanced clinical skills (suturing and tying-C7, neuropsychiatric
evaluation-C7) required at primary health care service level.
79
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.0.
2.0.
3.0.
4.0.
recall anatomy, histology and physiology of nervous system,
define biochemical and psychodynamical basis of behavior,
grade physical, psychosocial and cognitive development of child,
explain etiopathogenesis of clinical conditions (central and peripheral nervous system disorders,
epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent
in community and/or pose high risk for individual or community health, and/or life-threatening or
constitute an emergency related to nervous system and psychiatry,
5.0. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to to
nervous system and psychiatry,
6.0. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to nervous system and psychiatry,
7.0. describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms,
signs and findings in clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to
nervous system and psychiatry,
8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
• for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)
8.2. evaluation of emergency case (neurological emergencies-C7)
8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depressionC7, dementia-C7)
8.4. laboratory tests/examinations
8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal
neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PETC7)
8.6. point of care testing
8.7. making preliminary diagnosis or definitive diagnosis decision
8.8. making non-intervention or intervention decision
8.9. practicing non-intervention or intervention
8.10. referral/transport of healthy individual or patient
9.0. explain pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS
stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists,
general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs,
alcohols, drug dependence and abuse) that are effective on nervous system or on clinical
conditions related to nervous system and psychiatry,
10.0.describe professional standards, organizational ethics, and ethics in psychiatry,
11.0.describe phytotherapeutic agents (“HMPs, Nutraceutics”),
12.0. list common problems in medical research,
13.0. perform basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced
clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7),
required at primary health care service.
80
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE VII
NERVOUS SYSTEM and PSYCHIATRY
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0., 2.0., 4.0.-8.0., 10.0.
1.0., 2.0., 4.0.-8.0., 10.0.
1.0., 3.0.-8.0.
1.0., 3.0.-8.0.
1.0., 4.0., 7.0.
1.0., 4.0., 7.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
1.0., 4.0.-8.0.
2.0.
2.0.-8.0., 10.0.
4.0., 7.0.
4.0.-7.0, 8.4.
4.0.-8.0.
5.0., 6.0.
8.3.
8.3.
8.3.
8.5.
9.0.
9.0.
12.0.
FACULTY
DEPARTMENT
PCH
PCH
PED
PED
PT
PT
ANS
NR
NR
NRS
NRS
NRS
OPT
OPT
MG
C-PCH
PP
IDCM
IDCM
PH
FM
FM
FM
RAD
PC
PC
BS
LECTURER/INSTRUCTOR
H. Atalay
B. Akbaş
R. Cengizlier
A. Vitrinel
F. Özkan
I.D. Ekici
Ö. Köner
B. Aktekin
B. Örmeci
M.G.Yaşargil
B. Atalay
U. Türe
C.A.Yıldırım
V. Öztürk
A.Ç. Kuskucu
O. Zahmacıoglu
M. Kaçar
G. Çelik
M. Sönmezoğlu
R.E. Sezer
H. Akan
G. Izbırak
A. Akalın
A. Sarsılmaz
E. Genç
F. Kaleağasıoğlu
Ç. Kaspar
TOTAL
LEARNING OBJECTIVE
1.0., 4.0.-8.0.
1.0., 2.0., 4.0.-8.0., 10.0.
1.0., 4.0.-8.0.
FACULTY
DEPARTMENT
NR
PCH
NRS
CE
3
5
1
3
5
5
2
6
7
2
11
2
2
1
3
5
2
1
1
2
2
1
1
1
10
3
3
90
LECTURER/INSTRUCTOR
B. Ormeci
H. Atalay
B. Atalay
TOTAL
81
CE
2
1
2
5
NUMBER OF QUESTIONS
(MCQ)
FE
IE
Total
1
0
4
1
1
7
2
0
3
1
0
4
1
1
7
1
1
7
0
0
2
1
0
7
2
2
11
1
0
4
3
2
16
0
1
3
0
0
2
1
0
2
0
0
3
1
1
7
0
0
2
1
0
2
1
0
2
0
0
2
1
0
3
1
0
2
0
0
1
1
0
2
2
2
14
1
1
5
1
0
4
25/200
12/100
128
NUMBER OF QUESTIONS
(EMQ)
FE
IE
Total
2
1
2
5
-
PHASE III
COMMITTEE VII
I. WEEK
DAY
HOUR
30-Mar-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
31-Mar-2015
TUESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
01-Apr-2015
09.00-09.50
WEDNESDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-17.50
02-Apr-2015
THURSDAY
03-Apr-2015
FRIDAY
NERVOUS SYSTEM and PSYCHIATRY
SUBJECT
LECTURER
Introduction to Committee VII
Signs and Symptoms in Neurology
Cranial Nerves I
Cranial Nerves II
E. Vatanoğlu
B. Aktekin
B. Aktekin
B. Aktekin
Pathophysiology of Nervous System Diseases I
Pathophysiology of Nervous System Diseases II
Public Health and Aging I
Public Health and Aging II
Independent study hours
M. Kaçar
M. Kaçar
R.E. Sezer
R.E. Sezer
Cerebral Lobes and their Disorders
Demyelinating Disorders
Demyelinating Disorders
Infectious Disease of the Nervous System
B. Örmeci
B. Örmeci
B. Örmeci
R. Cengizlier
Infectious Diseases of CNS I
Infectious Diseases of CNS II
F. Özkan
F. Özkan
G. Kantarcı and
Committee VI
Coordination
Committee
Members
Discussion hour for the Committee VI exam
questions
Clinical Presentation, Anatomic Concepts and
Diagnosis in a Neurosurgical Patient
Pediatric Neurosurgery
Hydrocephalus
B. Atalay
B. Atalay
B. Atalay
Power analysis and sample size calculation
Power analysis and sample size calculation
Independent study hours
Ç. Kaspar
Ç. Kaspar
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Cerebrovascular Disease
Extrapyramidal System Disorders
Dementia
Acute and Chronic Meningitis, Encephalitis I
B. Örmeci
B. Örmeci
B. Örmeci
G. Çelik
Acute and Chronic Meningitis, Encephalitis II
Some Common Problems in Medical Research
Some Common Problems in Medical Research
Independent study hours
M. Sönmezoğlu
Ç. Kaspar
Ç. Kaspar
09.00-09.50
10.00-10.50
Peripheral Nerve Disorders
Epilepsy
Introduction to Central Nervous System
Pharmacology
Pharmacological Approach to Parkinsonism &
Other Movement Disorders
B. Aktekin
B. Aktekin
Pathology of Myelin & Neuronal Storage Diseases I
Pathology of Myelin & Neuronal Storage Diseases II
Developmental Disorders of CNS
Independent study hours
I.D. Ekici
I.D. Ekici
I.D. Ekici
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
82
E. Genç
E. Genç
II. WEEK
DAY
HOUR
SUBJECT
LECTURER
06-Apr-2015
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Neurodegenerative Disorders
Neurodegenerative Disorders I
Neurodegenerative Disorders II
Antiepileptics
A.Vitrinel
F. Özkan
F. Özkan
E. Genç
Neurosurgical Infections
Spinal Cord Compression and Spinal Tumors
Peripheral Nerve Compression Sydromes
Independent study hours
B. Atalay
B. Atalay
B. Atalay
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
Headache in Neurologic Patient
Neurological emergencies
Headache in Primary Care
Cranial Trauma & İntracranial Hemorrhage I
B. Örmeci
B. Örmeci
A. Akalın
F. Özkan
Cranial Trauma & İntracranial Hemorrhage II
15.00-15.50
Scientific Projects- III: Writing Project
16.00-16.50
17.00-17.50
Sedative / Hypnotic Drugs I
Sedative / Hypnotic Drugs II
F. Özkan
G. Yanıkkaya
Demirel
E. Genç
E. Genç
Neurology Clinical Study & Practice Group I
B. Aktekin
07-Apr-2015
TUESDAY
08-Apr-2015
WEDNESDAY
09-Apr-2015
THURSDAY
10-Apr-2015
FRIDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Surgical Neuroanatomy
Cerebrovascular Diseases in Neurosurgery I
Cerebrovascular Diseases in Neurosurgery II
U. Türe
U. Türe
U. Türe
Neurology Clinical Study & Practice Group II
B. Örmeci
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
Independent study hours
Independent study hours
Independent study hours
Pathology Lab Group I
Pathology Lab Group I
Independent study hours
83
F.Özkan/ I.D.Ekici
F.Özkan/ I.D.Ekici
III. WEEK
DAY
HOUR
SUBJECT
LECTURER
13-Apr-2015
MONDAY
09.00-09.50
10.00-10.50
Intracranial Tumors I
Intracranial Tumors II
Degenerative Diseases of the Spine and the
Spinal Cord I
Degenerative Diseases of the Spine and the
Spinal Cord II
M.G. Yaşargil
M.G. Yaşargil
Tumors of CNS I
Tumors of CNS II
Independent study hours
Independent study hours
I.D. Ekici
I.D. Ekici
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Functional Neurosurgery
Spinal Trauma in Neurosurgery
Cranial Trauma in Neurosurgery
Cerebral Malformations
B. Atalay
B. Atalay
B. Atalay
A. Vitrinel
Mental and Motor Development
Independent study hours
Independent study hours
Independent study hours
A. Vitrinel
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Neurosurgery: Clinical Practice –I
B. Atalay
Genetic Etiology of Mental Retardation I
Genetic Etiology of Mental Retardation II
A.Ç. Kuşkucu
A.Ç. Kuşkucu
Conventional Neuroradiological Examinations
Independent study hours
Independent study hours
Independent study hours
A. Sarsılmaz
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Neurosurgery: Clinical Practice –II
B. Atalay
Opioid Analgesics & Antagonists I
Opioid Analgesics & Antagonists II
E. Genç
E. Genç
CNS Stimulants and Hallusinogenic Drugs
Independent study hours
Independent study hours
Independent study hours
E. Genç
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
Introduction to Psychiatry
Signs and Symptoms in Psychiatry
Introduction to General Anesthesia
Anesthetic agents
H. Atalay
H. Atalay
Ö. Köner
Ö. Köner
Approach to Smoking Patient in Primary Care
Approach to the Patient with Dementia in
Primary Care
Local Anesthetics
General Anesthetics
H. Akan
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
14-Apr-2015
TUESDAY
15-Apr-2015
WEDNESDAY
16-Apr-2015
THURSDAY
17-Apr-2015
FRIDAY
15.00-15.50
16.00-16.50
17.00-17.50
84
B. Atalay
B. Atalay
H. Akan
E. Genç
E. Genç
IV. WEEK
DAY
HOUR
20-Apr-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
21-Apr-2015
TUESDAY
22-Apr-2015
WEDNESDAY
LECTURER
Developmental Psychopathology:
Risk and Protective Factors in Mental
Development
Psychopharmacology
Diseases of Optic Nerves and Visual Fields
Pupilla
H. Atalay
H. Atalay
C.A. Yıldırım
C.A. Yıldırım
F. Özkan/
I.D. Ekici
14.00-15.50
Pathology lab Group II
16.00-17.50
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
14.00-14.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Schizophrenia and Psychosis I
Schizophrenia and Psychosis II
Antipsychotic Drugs
Genetic Aspects of Psychiatric Disorders
H. Atalay
H. Atalay
F. Kaleağasıoğlu
A.Ç. Kuşkucu
Culture, Health and Illness
Epidemiology of Mental Disorders
Behavioral Determinants of Health and Disease
Independent study hours
Independent study hours
Independent study hours
R.E. Sezer
R.E. Sezer
R.E. Sezer
09.00-09.50
10.00-10.50
Introduction to child and adolescent psychiatry
Common Childhood Psychiatric Problems
Mental development in childhood and
adolescence
Depression in Primary Care
O. Zahmacıoğlu
O. Zahmacıoğlu
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
23-Apr-2014
THURSDAY
24-Apr-2014
FRIDAY
SUBJECT
CSL Group I
(Neuropsychiatric assessment)
O. Zahmacıoğlu
G. İzbırak
N.B. Akbaş/
O. Zahmacıoğlu/
B. Örmeci
National Holiday
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-17.50
Drug Addiction & Alcoholism
Organic Brain Syndromes
Mood Disorders
Paralytic Strabismus and Nistagmus
B. Akbaş
B. Akbaş
B. Akbaş
V. Öztürk
CSL Group IV
(Suturing materials and suturing technique)
U.A. Bingöl
85
V. WEEK
DAY
HOUR
SUBJECT
LECTURER
27-Apr-2014
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Anxiety Disorders I
Anxiety Disorders I
Psychotherapies
Bipolar Disease & Lithium
B. Akbaş
B. Akbaş
B. Akbaş
F. Kaleağasıoğlu
Drug Dependence & Abuse
Antidepressant Drugs
The Alcohols
Independent study hours
E. Genç
E. Genç
E. Genç
09.00-12.50
CSL Group III
(Neuropsychiatric assessment)
N.B.Akbaş/
O.Zahmacıoğlu/
B.Örmeci
CSL Group II
(Suturing materials and suturing technique)
T. Özler
CSL Group II
(Neuropsychiatric assessment)
N.B.Akbaş/
O.Zahmacıoğlu/
B.Örmeci
28-Apr-2014
TUESDAY
13.00-13.50
14.00-17.50
29-Apr-2014
WEDNESDAY
09.00-12.50
13.00-13.50
14.00-17.50
CSL Group I
(Suturing materials and suturing technique)
30-Apr-2015
09.00-12.50
FRIDAY
CSL Group IV
(Neuropsychiatric assessment)
H. Koyuncu
N.B.Akbaş/
O. Zahmacıoğlu/
B. Örmeci
13.00-13.50
14.00-17.50
01-May-2015
FRIDAY
CSL Group III
(Suturing materials and suturing technique)
LABOR’S DAY
86
H. Koyuncu
VI. WEEK
DAY
HOUR
SUBJECT
LECTURER
04-May-2015
MONDAY
09.00-17.50
Independent study hours
05-May-2015
TUESDAY
09.00-17.50
Independent study hours
06-May-2015
WEDNESDAY
09.00-17.50
Independent study hours
SPRING FEST
07-May-2015
THURSDAY
09.00-17.50
Independent study hours
SPRING FEST
08-May-2015 10.00-13.00 COMMITTEE EXAM
FRIDAY
87
SPRING FEST
SPRING FEST
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
DISTRIBUTION of LECTURE HOURS
MAY 11, 2015 – JUNE 05, 2015
COMMITTEE DURATION: 4 WEEKS


ABBR.
THEO.
PRAC.
LAB/CSL
DISCUSSION TOTAL
ORT
20
20
PTR
4
4
RHE
8
8

DISCIPLINE
ORTHOPAEDICS &
TRAUMATOLOGY
PHYSICAL THERAPY &
REHABILITATION
RHEUMATOLOGY

PATHOLOGY
PT
11

PATHOPHYSIOLOGY
PP
2
2

PHARMACOLOGY
PC
7
7

PUBLIC HEALTH
PH
5
5

FAMILY MEDICINE
FM
2
2

CLINICAL SKILLS LAB
CSL

MEDICAL GENETICS
MG
2
2


RAD
1
1
BED
2
2

RADIOLOGY
BIOMEDICAL ETHICS &
DEONTOLOGY
EMERGENCY MEDICINE
EM
1
1

BIOSTATISTICS
BS
2

TOTAL
1x2=2
(4 Groups)
13
1x3=3
(4 Groups)
67
0
5
3
1x2
4
2
74
Coordination Committee
HEAD
Melih Güven, MD Assoc. Prof
SECRETARY
Müge Bıçakçıgil, MD Assoc. Prof
Ece Aydoğ, MD Prof
Çağatay Uluçay, MD Assist. Prof
Mehtap Kaçar, MD PhD Assist. Prof.
(Co-coordinator)
MEMBER
MEMBER
MEMBER
88
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
LECTURERS
DISCIPLINE
FACULTY
ORTHOPAEDICS & TRAUMATOLOGY
Faik Altıntaş, MD, Prof.
Melih Güven, MD, Assoc.Prof.
Turhan Özler, MD, Assist. Prof.
Çağatay Uluçay, MD, Assist. Prof.
PHYSICAL THERAPY & REHABILITATION
Ece Aydoğ, MD, Prof.
RHEUMATOLOGY
Müge Bıçakçıgil, MD, Assoc. Prof
PATHOLOGY
Ferda Özkan, MD, Prof
Işın Doğan Ekici, MD, Assoc. Prof.
PATHOPHYSIOLOGY
Mehtap Kaçar, MD PhD, Assist. Prof.
PHARMACOLOGY
Ece Genç, PhD, Prof.
Ferda Kaleağasıoğlu, MD, Assoc. Prof.
PUBLIC HEALTH
Recep Erol Sezer, MD, Prof
Hale Arık Taşyıkan, MD, Assist. Prof
FAMILY MEDICINE
CLINICAL SKILLS LAB
Özlem Tanrıöver, MD, Assoc. Prof
Hülya Akan, MD, Assoc. Prof.
Turhan Özler, MD, Assist. Prof.
Çağatay Uluçay, MD, Assist. Prof.
MEDICAL GENETICS
Ayşegül Çınar Kuşkucu, MD, PhD Assist. Prof.
RADIOLOGY
Neslihan Taşdelen, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY
Elif Vatanoğlu, MD PhD, Assist Prof.
EMERGENCY MEDICINE
Sezgin Sarıkaya, MD, Assoc.Prof
BIOSTATISTICS
Çiğdem Kaspar, PhD, Assist. Prof.
89
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
AIMS and LEARNING OBJECTIVES
AIMS
In evidence based manner,
1. to remind knowledge on anatomy, histology and physiology of musculoskeletal system,
2. to convey knowledge on etiopathogenesis of clinical conditions which are frequent in community
and/or pose high risk for individual or community health, and/or life-threatening or constitute an
emergency related to musculoskeletal system,
3. to convey knowledge on epidemiology of clinical conditions which are frequent in community and/or
pose high risk for individual or community health, and/or life-threatening or constitute an emergency
related to musculoskeletal system,
4. to convey necessary knowledge on prevention of clinical conditions, and protection or improvement
of health against those clinical conditions related to musculoskeletal system,
5. to convey knowledge on mechanims of occurence for frequently encountered clinical complaints,
symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high
risk for individual or community health, and/or life-threatening or constitute an emergency related to
musculoskeletal system,
6. to convey necessary knowledge together with performance measures on health care processes,
clinical decision making process, clinical decisions and clinical practices required for managing
clinical conditions related to musculoskeletal system, which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency, at
the level of primary health care service,
7. to convey necessary knowledge on pharmacology of drugs that are effective on musculoskeletal
system or on clinical conditions related to musculoskeletal system,
8. to convey necessary knowledge on ethics in biomedical research,
9. to convey necessary knowledge on clinical research methods and searching medical literature,
10. to convey necessary knowledge on phytotherapeutic agents,
11. to equip with basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical
examination of musculoskeletal system-C8) required at primary health care service level.
90
LEARNING OBJECTIVES
At the end of this committee, student should be able to:
1.0. recall anatomy, histology and physiology of musculoskeletal system,
2.0. explain etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative,
onocological conditions of bone, rheumotological disorders, disaeses/disorders of connective
tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose
high risk for individual or community health, and/or life-threatening or constitute an emergency
related to musculoskeletal system,
3.0. explain epidemiology of clinical conditions which are frequent in community and/or pose high risk
for individual or community health, and/or life-threatening or constitute an emergency related to
musculoskeletal system,
4.0. explain prevention of clinical conditions, and protection or improvement of health against those
clinical conditions related to musculoskeletal system,
5.0. describe mechanisms of occurrence for frequently encountered clinical complaints, symptoms,
signs and findings in clinical conditions which are frequent in community and/or pose high risk for
individual or community health, and/or life-threatening or constitute an emergency related to
musculoskeletal system,
6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
• for healthy conditions in an individual or community with a request against clinical conditions
that pose risks,
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a
community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or
community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of
reliability, practicality and outcomes,
• health care processes, clinical decision making process, clinical decisions and clinical practices
which are required for management at primary health care service level:
6.1. practice of history taking and physical examination (musculoskeletal-C8)
6.2. evaluation of emergency case (trauma-C8)
6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
6.4. laboratory tests/examinations (monitarization of drug therapy-C8)
6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological
examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7.0. explain pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants) that are effective
on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8.0. explain effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions
related to musculoskeletal system,
9.0. list ethical principles in biomedical research,
10.0.explain use of biostatistics in clinical research and for evidence search in medical literature,
11.0. perform basic clinical skills, practiced on phantom models (peripheral venous catheter insertionC8), and advanced clinical skills, practiced on simulated/standardized patients (physical
examination of musculoskeletal system-C8), required at primary health care service.
91
YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE VIII
MUSCULOSKELETAL SYSTEM
QUESTION DISTRIBUTION TABLE
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
1.0., 2.0., 5.0.
1.0., 2.0., 5.0.
1.0., 2.0., 5.0.
2.0.
3.0., 4.0.
3.0., 4.0.
6.2.
6.3.
6.3.
6.5.
7.0.
7.0.
9.0.
10.0.
FACULTY
DEPARTMENT
ORT
ORT
ORT
ORT
PTR
RHE
PP
PT
PT
MG
PH
PH
EM
FM
FM
RAD
PC
PC
BED
BS
LECTURER/INSTRUCTOR
F. Altıntas
T. Özler
Ç. Uluçay
M. Güven
E. Aydog
M. Bıçakçıgil
M. Kaçar
F. Özkan
I.D. Ekici
A.Ç. Kuşkucu
R.E. Sezer
H.A.Taşyıkan
S. Sarıkaya
H. Akan
Ö. Tanrıöver
N. Taşdelen
F. Kaleağasıoğlu
E. Genç
E. Vatanoğlu
Ç. Kaspar
TOTAL
LEARNING OBJECTIVE
1.0.-6.0.
1.0.-6.0.
1.0.-6.0.
FACULTY
DEPARTMENT
RHE
ORT
PTR
LECTURER/INSTRUCTOR
M. Bıçakçıgil
M.Güven
E. Aydoğ
TOTAL
92
NUMBER OF QUESTIONS
(MCQ)
CE
FE
IE
Total
6
2
1
9
7
1
1
9
5
3
2
10
11
2
1
14
4
1
1
6
8
2
1
11
2
1
0
3
10
2
1
13
6
1
1
8
2
1
0
3
4
1
1
6
3
1
0
4
1
0
0
1
1
1
0
2
1
1
0
2
1
1
0
2
6
1
1
8
3
1
0
4
3
1
0
4
6
1
1
8
90
25/200
12/100
127
NUMBER OF QUESTIONS
(EMQ)
CE
FE
IE
Total
2
2
2
2
1
1
5
5
-
PHASE III
COMMITTEE VIII
I. WEEK
DAY
HOUR
11-May-2015
09.00-09.50
MONDAY
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
12-May-2015
TUESDAY
Pathophysiology of Musculoskeletal System
Disorders I
Pathophysiology of Musculoskeletal System
Disorders II
Independent study hours
Independent study hours
M. Kaçar
Discussion hour for the Committee VII
exam questions
M. Kaçar
B. Atalay and
Committee VII
Coordination
Committee Members
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
Developmental Disorders of the Skeleton
Congenital Dislocation of the Hip
Congenital & Metabolic Diseases of Bone I
Congenital & Metabolic Diseases of Bone II
M. Güven
M. Güven
F. Özkan
F. Özkan
Introduction to Occupational Health
Ethics of Testing and Screening
Ethics of Testing and Screening
Independent study hours
R.E. Sezer
E. Vatanoğlu
E. Vatanoğlu
09.00-09.50
10.00-10.50
Osteomyelitis and Septic Artritis
Upper Extremity Disorders
Inflammatory Polyarthritis & Rheumatoid
Arthritis
Bone and Joint Infections
M. Güven
Ç. Uluçay
Nonsteroidal Antiinflammatory Drugs I
Nonsteroidal Antiinflammatory Drugs II
Independent study hours
Independent study hours
E. Genç
E. Genç
Osteoporosis
Degenerative Osteoarthrosis
Degenerative Joint Disease
Independent study hours
Ç. Uluçay
F. Altıntaş
F. Özkan
13.00-17.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17.00-17.50
15-May-2015
FRIDAY
LECTURER
M. Kaçar
F. Altıntaş
R.E. Sezer
R.E. Sezer
Ç. Uluçay
Ç. Uluçay
12.00-12.50
14-May-2015
THURSDAY
SUBJECT
Introduction to Committee VIII
Introduction to Musculoskeletal System
Public Health and Physical Activity I
Public Health and Physical Activity II
Lower Extremity Disorders
Foot Deformities
Epidemiology, Prevention and Control of
Occupational Diseases and Injuries I
Epidemiology, Prevention and Control of
Occupational Diseases and Injuries II
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
13-May-2015
WEDNESDAY
MUSCULOSKELETAL SYSTEM
09.00-09.50
10.00-10.50
11.00-11.50
12.00-17.50
93
H.A. Taşyıkan
H.A. Taşyıkan
M. Bıçakçıgil
I.D. Ekici
II. WEEK
DAY
HOUR
18-19-May-2015
MONDAYTUESDAY
20-May-2015
WEDNESDAY
Neuromuscular Disease
Spondylarthropaties
Connective Tissue Disorders I
Connective Tissue Disorders II
M. Güven
M. Bıçakçıgil
M. Bıçakçıgil
M. Bıçakçıgil
Soft Tissue Pain
Osteoporosis and Osteoarthritis Treatment,
Rehabilitation
Independent study hours
Independent study hours
E. Aydoğ
09.00-09.50
13.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
Low Back, Hip and Ankle Pain
Neck, Shoulder and Wrist Pain
Sport Injuries I
Sport Injuries II
E. Aydoğ
E. Aydoğ
T. Özler
T. Özler
Medical Literature
Medical Literature
Vasculitis I
Vasculitis II
Ç. Kaspar
Ç. Kaspar
M. Bıçakçıgil
M. Bıçakçıgil
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
Miscellanous Rheumotological Disorders I
Miscellanous Rheumotological Disorders II
Microsurgery and Replantation
Trauma
M. Bıçakçıgil
M. Bıçakçıgil
T. Özler
T. Özler
Skeletal Muscle Relaxants
Disease Modifying Antirheumatic Drugs
16.00-16.50
Pharmacology Case Studies
E. Genç
F. Kaleağasıoğlu
E. Genç /
F. Kaleağasıoğlu
17:00-17:50
Independent study hours
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
16.00-16.50
17:00-17:50
22-May-2015
FRIDAY
LECTURER
National Holiday
15.00-15.50
21-May-2015
THURSDAY
SUBJECT
94
E. Aydoğ
III. WEEK
DAY
HOUR
SUBJECT
LECTURER
25-May-2015
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
Traumatic Dislocations
Spinal Deformities
Benign Tumors of Bone
Malignant Tumors of Bone
Ç. Uluçay
Ç. Uluçay
M. Güven
M. Güven
Principles of Fracture Healing
Myopathies
Independent study hours
Independent study hours
F. Altıntaş
I.D. Ekici
09.00-09.50
10.00-10.50
11.00-11.50
Fractures of Children
Vasculitis/I
Vasculitis/I
Approach to the Patient with Backpain in
Primary Care
Fibromyalgia in Primary Care
M. Güven
F. Özkan
F. Özkan
Imaging of Musculosceletal System
Independent study hours
Independent study hours
N. Taşdelen
26-May-2015
TUESDAY
12.00-12.50
13.00-13.50
14.00-14.50
15.00-15.50
16.00-16.50
17:00-17:50
27-May-2015
WEDNESDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Independent study hours
Independent study hours
Independent study hours
Independent study hours
T. Özler/ Ç.Uluçay
Tumors of Soft Tissues I
Tumors of Soft Tissues II
Skeletal Dysplasias
Muscular Dystrophies
F. Özkan
F. Özkan
A.Ç. Kuşkucu
A.Ç. Kuşkucu
Initial Approach to Trauma Patient
S. Sarıkaya
CSL Group IV
(Physical examination of the musculoskeletal
system)
T. Özler/ Ç.Uluçay
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
Upper Extremity Trauma
Lower Extremity Trauma
Clinical Trials
Clinical Trials
T. Özler
T. Özler
Ç. Kaspar
Ç. Kaspar
14.00-16.50
CSL Group I
(Physical examination of the musculoskeletal
system)
Independent study hours
17:00-17:50
09.00-09.50
13.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-14.50
15.00-17.50
29-May-2015
FRIDAY
H. Akan
CSL Group II
(Physical examination of the musculoskeletal
system)
Independent study hours
14.00-16.50
28-May-2015
THURSDAY
Ö. Tanrıöver
T. Özler/ Ç.Uluçay
17:00-17:50
95
IV. WEEK
DAY
HOUR
SUBJECT
LECTURER
01-June-2015
MONDAY
09.00-09.50
10.00-10.50
11.00-11.50
12.00-12.50
13.00-13.50
14.00-16.50
Bone tumors I
Bone tumors II
Pathology Lab Groups: I-II
I.D. Ekici
I.D. Ekici
I.D. Ekici
CSL Group III
(Physical examination of the musculoskeletal
system)
T. Özler/ Ç.Uluçay
17:00-17:50
Independent study hours
02-June-2015
TUESDAY
09.00-17.50
Independent study hours
03-June-2015
WEDNESDAY
09.00-17.50
Independent study hours
04-June-2015
THURSDAY
09.00-17.50
Independent study hours
05-June-2015
10.0013.00
COMMITTEE EXAM
FRIDAY
14.0015.00
Discussion hour for the Committee VIII
exam questions
08-June-2015
MONDAY
09:0018:00
OSCE-II EXAM
29-June-2015
MONDAY
FINAL EXAM
24-July-2015
FRIDAY
INCOMPLETE EXAM
96
M. Güven and
Committee VIII
Coordination
Committee members
_________________________________________________________________________________
Contact
Faculty Secretary:
Tel: +90 216 578 05 93
Dean Secretary:
Tel: +90 216 578 05 05-06
Fax: +90 216 578 05 75
Student Affairs:
Tel: 0216 578 06 86
Document Affairs:
Tel: 0216 578 05 23
PHASE III COORDINATION COMMITTEE
Gülderen Yanıkkaya Demirel MD, Assoc. Prof. (Coordinator) 0216 578 00 00 (3218)/
[email protected]
Özlem Tanrıöver, Assoc. Prof. (Co-coordinator) 0216 578 00 00 (3742) / [email protected]
Ayşegül Kuşkucu, MD, PhD Assist. Prof. (Co-coordinator) 0216 578 00 00 (5777)/
[email protected]
Elif Vatanoğlu, MD, Assist. Prof. (Co-coordinator) 0216 578 00 00(3078)/ [email protected]
Mehtap Kaçar, MD, Assist. Prof. (Co-coordinator) 0216 578 00 00 (1419)/ [email protected]
ICP III COORDINATION COMMITTEE
Özlem Tanrıöver MD, Assoc. Prof. (ICP Coordinator) 216 578 00 00 (3742)/ [email protected]
A. Arzu Akalın MD, Assist. Prof. (ICP Co-coordinator) 216 578 00 00 (1525)/ [email protected]
Turhan Özler MD, Assist. Prof. (ICP Co-coordinator) 0216 578 00 00 (4051)/ [email protected]
Address:
Yeditepe University Faculty of Medicine
İnönü Mah., Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul
Web: www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
e-mail: [email protected]
[email protected]________________
97
YEDİTEPE UNIVERSITY
FACULTY of MEDICINE
İnönü Mahallesi, Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul
Tel: (+90 216) 578 00 00
www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
[email protected]
Download

YEDİTEPE UNIVERSITY FACULTY of MEDICINE PHASE III